[Skip to nav](https://www.moffitt.org/research-science/researchers/rami-komrokji#menu-mobile) [Skip to content](https://www.moffitt.org/research-science/researchers/rami-komrokji#main-content)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/rami-komrokji/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/rami-komrokji/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate") Search
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/rami-komrokji)
    * [ Cancers ](https://www.moffitt.org/cancers/)
      * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
      * [Acute Myeloid Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myeloid Leukemia \(AML\)")
      * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
      * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
      * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
      * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
      * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
      * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
      * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
      * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
      * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
      * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
      * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
      * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
      * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
      * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
      * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
      * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
      * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
      * [Chronic Myeloid Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myeloid Leukemia \(CML\)")
      * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
      * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
      * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
      * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
      * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
      * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
      * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
      * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
      * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
      * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
      * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
      * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
      * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
      * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
      * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
      * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
      * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
      * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
      * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
      * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
      * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
      * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
      * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
      * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
      * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
      * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
      * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
      * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
      * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
      * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
      * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
      * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
      * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
      * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
      * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
      * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
      * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
      * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
      * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
      * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
      * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
      * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
      * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
      * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
      * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
      * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
      * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
      * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
      * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
      * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
      * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
      * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
      * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
      * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
      * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
      * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
      * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
      * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
      * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
      * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
      * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")
    * [ Treatments ](https://www.moffitt.org/treatments/)
      * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
      * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
      * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
      * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
      * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
      * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
      * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
      * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
      * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
      * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
      * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
      * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
      * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
      * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
      * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
      * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
      * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
      * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
      * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
      * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
      * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
      * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")
    * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
      * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
      * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
      * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
      * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
      * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
      * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")
    * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/)
      * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
      * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
      * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
      * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
      * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
      * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")
    * [ ![](https://www.moffitt.org/contentassets/5f17f2115eca48a1aa7faa610608f778/clinical-trials.jpg) Search Clinical Trials  Moffitt participates in over 400 clinical trials. Find a trial that is right for you. ](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Search Clinical Trials")
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/rami-komrokji)
    * [ Patient & Family ](https://www.moffitt.org/patient-family/)
    * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/)
      * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
      * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
      * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
      * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
      * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
      * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
      * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
      * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
      * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
      * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
      * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
      * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
      * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")
    * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/)
      * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
      * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
      * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
      * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
      * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
      * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
      * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
      * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
      * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
      * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")
    * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/)
      * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
      * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
      * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
      * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
      * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
      * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
      * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
      * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
      * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")
    * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/)
      * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
      * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
      * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
      * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
      * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
      * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
      * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
    * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/)
      * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")
    * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/)
      * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
      * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
      * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
      * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")
    * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/)
      * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
      * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
      * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
      * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")
    * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/)
      * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
      * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
      * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
      * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
      * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
      * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
      * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
      * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
      * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
      * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
      * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
      * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
      * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
      * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
      * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
      * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
      * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
      * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
      * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
      * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
      * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
      * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
      * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
      * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
      * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
      * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
      * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
      * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
      * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
      * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
      * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
      * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
      * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
      * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
      * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
      * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
      * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
      * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
      * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
      * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
      * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
      * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
      * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
      * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
      * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
      * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
      * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
      * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
      * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
      * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
      * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
      * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
      * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
      * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
      * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
      * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
      * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
      * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
      * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
      * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
      * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
      * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
      * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
      * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
      * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
      * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
      * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
      * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
      * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
      * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
      * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
      * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
      * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
      * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
      * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
      * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
      * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
      * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
      * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
      * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
      * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
      * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
      * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
      * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
      * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
      * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
      * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
      * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
      * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
      * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
      * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
      * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
      * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
      * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
      * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
      * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
      * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
      * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
      * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
      * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
      * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
      * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
      * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
      * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
      * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
      * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
      * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
      * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
      * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
      * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
      * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
      * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
      * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
      * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
      * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
      * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")
    * [ ![Friends supporting woman with cancer ](https://www.moffitt.org/globalassets/images/content-images/patient--family/women-cancer-640.jpg) Taking Care of Your Health  Taking Care of Your Health features cancer-related information, health tips, patient stories and more. ](https://www.moffitt.org/taking-care-of-your-health/ "Taking Care of Your Health")
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/rami-komrokji)
    * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
    * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/)
      * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
      * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
      * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
      * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
      * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
      * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
      * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
      * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
      * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
      * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
      * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
      * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
      * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
      * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
      * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
      * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
      * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
      * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
      * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
      * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
      * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
      * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
      * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
      * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
      * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
      * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
      * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")
    * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
    * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/)
      * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
      * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")
  * [Research](https://www.moffitt.org/research-science/researchers/rami-komrokji)
    * [ Research Science ](https://www.moffitt.org/research-science/)
    * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/)
      * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
      * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
      * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
      * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
      * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")
    * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/)
      * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
      * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
      * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
      * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
      * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")
    * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/)
      * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
      * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")
    * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/)
      * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
      * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
      * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
      * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
      * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
      * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
      * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")
    * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/)
      * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
      * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
      * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
      * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
      * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
      * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
      * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
      * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
      * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
      * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
      * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
      * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
      * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")
    * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/)
      * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
      * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")
    * [ Administration ](https://www.moffitt.org/research-science/administration/)
      * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")
    * [ ![Research fellows in a lab](https://www.moffitt.org/contentassets/a7d26515856847ad8ebe488477e34948/research-training.jpg) Research Education and Training  We are interested in recruiting scholars who have a profound interest in preventing, treating and curing cancer. ](https://www.moffitt.org/education/research-education-and-training/ "Research Education and Training")
  * [Training & Education](https://www.moffitt.org/research-science/researchers/rami-komrokji)
    * [ Education ](https://www.moffitt.org/education/)
    * [ Medical Education ](https://www.moffitt.org/education/medical-education/)
      * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
      * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
      * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
    * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/)
      * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
      * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
      * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
      * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
      * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
      * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
      * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
      * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
      * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")
    * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/)
      * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
      * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
      * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
      * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
      * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")
    * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/)
      * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
      * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
      * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
      * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
      * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
      * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
      * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
      * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
      * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
      * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
      * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
      * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
      * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
      * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
      * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
      * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
      * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
      * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
      * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
      * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
      * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
      * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
      * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
      * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")
    * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)
  * [Give](https://www.moffitt.org/research-science/researchers/rami-komrokji)
    * [ Give ](https://www.moffitt.org/give/)
    * [ Why Give? ](https://www.moffitt.org/give/why-give/)
      * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
      * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
      * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
      * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
      * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
      * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")
    * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/)
      * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
      * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
      * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
      * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
      * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
      * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
      * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
      * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
      * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
      * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")
    * [ Get Involved ](https://www.moffitt.org/give/get-involved/)
      * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
      * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
      * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
      * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
      * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
      * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
      * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")
    * [ ![A researcher holds a Moffitt License Plate](https://www.moffitt.org/contentassets/fff003985b6341a8b2d684da79916350/ways-to-give.jpg) Ways to Give  Cancer touches all of us. Our mission - to contribute to the prevention and cure of cancer - depends on your support.  ](https://www.moffitt.org/give/ways-to-give/ "Ways to Give")


# Rami Komrokji, MD
![Rami  Komrokji](https://www.moffitt.org/globalassets/images/researchers_bio/KomrokjiRami_4734.jpg)
Rami Komrokji, MD 
Vice Chair, Department of Malignant Hematology
**Specialty:** Internal Medicine 
**Program:** Malignant Hematology 
**Research Program:** Molecular Medicine Program 
[ Contact ](https://eforms.moffitt.org/ContactResearchersForm?PERID=4734)
  * ## Overview
Our clinical trials focus on novel therapies for myelodysplastic syndromes, myeloproliferative neoplasms and acute myeloid leukemia. Our large myeloid institution research database serves as robust Real-world dataset and provides sets for clinical and translational research.
### Associations
    * Malignant Hematology
    * Experimental Therapeutics Program
    * Molecular Medicine Program
### Education & Training
**Internship:**
    * Case Western University, St. Vincent Program - Intern
**Continuing Education:**
    * Strong Memorial Hospital, University of Rochester - Hematopoietic Stem Cell Transplantation
**Board Certification:**
    * Internal Medicine - Hematology
**Fellowship:**
    * Strong Memorial Hospital, University of Rochester - Hematology/Oncology
**Residency:**
    * Case Western University, St. Vincent Program - Internal Medicine
**Medical School:**
    * Jordan University School of Medicine - MBBS
  * ## Research Interest
Dr. Komrokji’s research interests are in Phase I and II Clinical Trials, and in outcome research in hematologic malignancies with focus on myeloid neoplasms. His clinical interests are Myelodysplastic syndromes (MDS), Acute Leukemias, and Myeloproliferative neoplasms.
  * ## Participating Trials
[ Clinical Trial 21247 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21247/ "Clinical Trial 21247")   
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor   
Condition: Malignant Hematology   
Intervention: Imetelstat (GRN163L)   
Status: Open 
[ Clinical Trial 21405 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-21405/ "Clinical Trial 21405")   
Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in lower Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN)   
Condition: Malignant Hematology   
Intervention: ACE-536 (Luspatercept); Luspatercept ()   
Status: Open 
[ Clinical Trial 23208 ](https://www.moffitt.org/clinical-trials-and-studies/clinical-trial-23208/ "Clinical Trial 23208")   
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The "ELEMENT-MDS" Trial   
Condition: Malignant Hematology   
Intervention: ACE-536 (Luspatercept); Epoetin Alfa (erythropoietin); Luspatercept ()   
Status: Open 
**If you believe you are eligible for one of these trials or studies, please call  
[813-745-6100](tel:+813-745-6100) or toll-free [1-800-679-0775](tel:+1-800-679-0775). **
  * ## Publications
    * Reynolds SB, Komrokji R, Kuykendall AT. The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies. Blood Lymphat Cancer. 2025 Sep.15:181-192. Pubmedid: [41030319](https://www.ncbi.nlm.nih.gov/pubmed/41030319). Pmcid: PMC12477285. 
    * Aguirre LE, Ball S, Jain A, Ali NA, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS. Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression. Clin Lymphoma Myeloma Leuk. 2025 Sep.25(9):661-671. Pubmedid: [40254502](https://www.ncbi.nlm.nih.gov/pubmed/40254502). 
    * Komrokji RS, Supina D, Navada S, Potluri R, Tyagi R, Werwath T, Xie Z, Padron E, Sallman DA. Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims. Clin Lymphoma Myeloma Leuk. 2025 Oct.25(10):e740-e749. Pubmedid: [40410022](https://www.ncbi.nlm.nih.gov/pubmed/40410022). 
    * Gisriel SD, Aakash F, Bennett JM, Hasserjian RP, Loghavi S, DeZern AE, Santini V, Savona MR, Brunner AM, Buckstein R, Wei AH, Della Porta MG, Komrokji RS, Borate UM, Sekeres MA, Platzbecker U, Fenaux P, Roboz GJ, van de Loosdrecht A, Zeidan AM, Xu ML. Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms. Arch Pathol Lab Med. 2025 Oct.149(10):968-976. Pubmedid: [40059041](https://www.ncbi.nlm.nih.gov/pubmed/40059041). 
    * Kruer TL, Quintana-Gonzalez A, Newman HL, Ferrall-Fairbanks MC, Zhang L, McLemore AF, Neupane S, Yang Q, Ben-Crentsil NA, Balasis ME, Letson CT, Komrokji RS, Chaudhry S, Totiger TM, Traina JA, Figueroa ME, Ryder CB, Cluzeau T, Taylor J, Sallman DA, Padron E. XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies. Blood. 2025 Oct.146(18):2244-2258. Pubmedid: [40737597](https://www.ncbi.nlm.nih.gov/pubmed/40737597). 
    * Xie Z, Al Ali N, Zhang L, Papenhausen P, Volpe VO, Chan O, Kuykendall A, Yun S, Walker A, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji RS. Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. Blood Neoplasia. 2025 May.2(2):100062. Pubmedid: [40453136](https://www.ncbi.nlm.nih.gov/pubmed/40453136). Pmcid: PMC12067887. 
    * Mina A, Komrokji RS. How I treat higher-risk MDS. Blood. 2025 May.145(18):2002-2011. Pubmedid: [39808802](https://www.ncbi.nlm.nih.gov/pubmed/39808802). 
    * Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM. A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Ann Hematol. 2025 Mar.104(3):1577-1585. Pubmedid: [40153010](https://www.ncbi.nlm.nih.gov/pubmed/40153010). Pmcid: PMC12031784. 
    * Sekeres MA, Santini V, Díez-Campelo M, Komrokji RS, Fenaux P, Savona MR, Madanat YF, Valcárcel-Ferreiras D, Oliva EN, Regnault A, Creel K, Sengupta N, Dougherty S, Shah S, Sun L, Wan Y, Navada S, Zeidan AM, Platzbecker U. Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. Leuk Lymphoma. 2025 Mar.66(3):529-534. Pubmedid: [39535901](https://www.ncbi.nlm.nih.gov/pubmed/39535901). 
    * Mina A, McGraw KL, Cunningham L, Kim N, Jen EY, Calvo KR, Ehrlich LA, Aplan PD, Garcia-Manero G, Foran JM, Garcia JS, Zeidan AM, DeZern AE, Komrokji RS, Sekeres MA, Scott BL, Buckstein RJ, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic SZ, Norsworthy KJ. Advancing drug development in myelodysplastic syndromes. Blood Adv. 2025 Mar.9(5):1095-1104. Pubmedid: [39786387](https://www.ncbi.nlm.nih.gov/pubmed/39786387). Pmcid: PMC11914162. 
    * Borate U, Pugh K, Waller A, Welkie RL, Huang Y, Bewersdorf JP, Stahl M, DeZern AE, Platzbecker U, Sekeres MA, Wei AH, Buckstein RJ, Roboz GJ, Savona MR, Loghavi S, Hasserjian RP, Fenaux P, Sallman DA, Hourigan CS, Della Porta MG, Nimer S, Little RF, Santini V, Efficace F, Taylor J, Garcia-Manero G, Odenike O, Kim TK, Halene S, Komrokji RS, Griffiths EA, Greenberg PL, Xu ML, Xie Z, Bejar R, Sanz GF, Patnaik MM, Figueroa M, Carraway HE, Abdel-Wahab O, Starczynowski D, Padron E, Boultwood J, Gore S, Daver NG, Churpek JE, Majeti R, Bennett JM, List AF, Brunner AM, Zeidan AM. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025 Mar.145(13):1369-1381. Pubmedid: [40146152](https://www.ncbi.nlm.nih.gov/pubmed/40146152). Pmcid: PMC11969261. 
    * Komrokji Z, Ali NA, Xie Z, Chan O, Yun S, Walker A, Lancet J, Kuykendall A, Sallman D, Padron E, Komrokji RS. Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML). Leuk Res. 2025 Mar.150:107662. Pubmedid: [39921921](https://www.ncbi.nlm.nih.gov/pubmed/39921921). 
    * Takaoka K, Komrokji R, Chien K, Montalban-Bravo G, Salman JB, Urrutia S, Bataller A, Bazinet A, Kekedjian J, Al Ali NH, Sallman D, Padron E, Xie Z, Kanagal-Shamanna R, Tang G, Yang H, Rodriguez-Sevilla JJ, Garcia-Manero G, Sasaki K. Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion. Leuk Res. 2025 Mar.150:107661. Pubmedid: [39938357](https://www.ncbi.nlm.nih.gov/pubmed/39938357). 
    * Zampini M, Riva E, Lanino L, Sauta E, Antunes Dos Reis R, Ejarque RMA, Maggioni G, Termanini A, Merlotti A, Campagna A, Dall'Olio L, Kulasekararaj A, Calvi M, Di Vito C, Bonometti A, Rahal D, Croci G, Boveri E, Gianelli U, Ponzoni M, Caselli R, Albertazzi S, Todisco G, Ubezio M, Crisafulli L, Frigo A, Lugli E, Mosca E, Acha P, Ghisletti S, Nicassio F, Santoro A, Diez-Campelo M, Solé F, Ades L, Platzbecker U, Santini V, Fenaux P, Haferlach T, Sallman D, Garcia-Manero G, Mavilio D, Remondini D, Castellani G, D'Amico S, Zeidan AM, Komrokji R, Kordasti S, Ficara F, Della Porta MG. Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2025 Jun.43(18):2069-2083. Pubmedid: [40315418](https://www.ncbi.nlm.nih.gov/pubmed/40315418). Pmcid: PMC12169866. 
    * Sallman DA, Komrokji RS, Dezern AE, Sebert M, Garcia-Manero G, Rahmé R, Winer ES, Lehmann-Che J, Roboz GJ, Madelaine I, Sekeres MA, Peterlin P, Chan O, Beyne-Rauzy O, Kuykendall A, Recher C, McLemore A, Stamatoullas A, Zhang L, Willems L, Mo Q, Raffoux E, Nardelli L, Berthon C, Al Ali NH, Quesnel B, Padron E, Kantarjian HM, List AF, Ades L, Lancet JE, Fenaux P, Cluzeau T. Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML. Hemasphere. 2025 Jul.9(7):e70164. Pubmedid: [40657305](https://www.ncbi.nlm.nih.gov/pubmed/40657305). Pmcid: PMC12255903. 
    * Komrokji RS, Ammad-Ud-Din M, Ali NHA, Xie Z, Chan O, Kuykendall AT, Yun S, Walker AR, Lancet J, Padron E, Sallman DA. Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival. Clin Lymphoma Myeloma Leuk. 2025 Jul.25(7):e487-e490. Pubmedid: [40113545](https://www.ncbi.nlm.nih.gov/pubmed/40113545). 
    * Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Pozharskaya V, Rose S, Keeperman K, Lai Y, Kalsekar S, Aggarwal B, Miteva D, Valcárcel D, Fenaux P, Shortt J, Della Porta MG, Platzbecker U. Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial. Adv Ther. 2025 Jul.42(7):3576-3589. Pubmedid: [40377899](https://www.ncbi.nlm.nih.gov/pubmed/40377899). Pmcid: PMC12182481. 
    * Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, Kadia TM, Ravandi F, Chien K, Van Hyfte G, Mazumdar M, Saliba A, Mangaonkar A, Lasho T, Al-Kali A, Kremyanskaya M, Feld J, Silverman LR, Komrokji R, Mascarenhas J, Padron E, Garcia-Manero G, Sallman DA, Patnaik MM, Montalban-Bravo G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2025 Jan.39(1):257-260. Pubmedid: [39533069](https://www.ncbi.nlm.nih.gov/pubmed/39533069). 
    * Jain AG, Volpe VO, Wang C, Ball S, Tobon K, Chan O, Padron E, Kuykendall A, Lancet JE, Komrokji R, Sallman DA, Sweet KL. Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Ann Hematol. 2025 Jan.104(1):307-315. Pubmedid: [39243312](https://www.ncbi.nlm.nih.gov/pubmed/39243312). 
    * Consagra A, Lanino L, Al Ali NH, Aguirre L, Xie Z, Chan O, Andreossi G, Raddi MG, Rigodanza L, Sanna A, Mattiuz G, Tofacchi E, Amato C, Tanturli M, De Pourcq S, Walker A, Kuykendall A, Lancet J, Padron E, Sallman DA, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Maggioni G, Campagna A, Della Porta MG, Santini V, Komrokji RS. Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS. Hemasphere. 2025 Feb.9(2):e70086. Pubmedid: [39944234](https://www.ncbi.nlm.nih.gov/pubmed/39944234). Pmcid: PMC11814532. 
    * Carraway HE, Brunner AM, Lai CE, Luskin MR, Park J, Perl AE, Stein EM, Wang ES, Zeidan AM, Zeidner JF, Komrokji R. Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Clin Lymphoma Myeloma Leuk. 2025 Aug.25(8):583-589. Pubmedid: [40187939](https://www.ncbi.nlm.nih.gov/pubmed/40187939). 
    * Csizmar CM, Natu A, Gurney M, Fathima S, Alsugair AKA, Kanagal-Shamanna R, Loghavi S, Bazinet A, Chien K, Hammond D, DiNardo C, Kadia T, Ravandi-Kashani F, Pemmaraju N, Sasaki K, Lasho TL, Finke CM, Al-Kali A, Alkhateeb H, Begna K, Gangat N, Hefazi Torghabeh M, Matin A, Mangaonkar AA, Saliba AN, Tefferi A, Garcia-Manero G, Kantarjian HM, Komrokji RS, Xie Z, Ali NA, Sallman D, Padron E, Montalban-Bravo G, Patnaik MM. Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes. Leukemia. 2025 Aug.39(8):2030-2034. Pubmedid: [40555734](https://www.ncbi.nlm.nih.gov/pubmed/40555734). 
    * Sekeres MA, Venugopal S, Chandhok NS, Watts JM, Bradley T, Taylor J, Sallman DA, Xie Z, Padron E, Zyborowicz E, Anderson Chadha C, Carter J, Heggen C, Sullivan S, Gurska L, Komrokji RS. Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings. Leuk Lymphoma. 2025 Aug.1-5. Pubmedid: [40853277](https://www.ncbi.nlm.nih.gov/pubmed/40853277). 
    * Gharaee N, Wegrzyn-Woltosz J, Jiang J, Akhade VS, Bridgers J, Stubbins RJ, Hiwase D, Kutyna MM, Chan O, Komrokji R, Padron E, Deng Y, Cole G, Umlandt P, Fuller M, Kim A, Karsan A. Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm. Leukemia. 2025 Apr.39(4):917-928. Pubmedid: [40000845](https://www.ncbi.nlm.nih.gov/pubmed/40000845). Pmcid: PMC11976265. 
    * Porta MGD, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Sep.11(9):e646-e658. Pubmedid: [39038479](https://www.ncbi.nlm.nih.gov/pubmed/39038479). 
    * Gerds AT, Harrison CN, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji RS, Bose P, Kremyanskaya M, Mead A, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi AC, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv. 2024 Sep.8(17):4511-4522. Pubmedid: [38820422](https://www.ncbi.nlm.nih.gov/pubmed/38820422). Pmcid: PMC11395770. 
    * Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, Finke CM, Dean C, Natu A, Mangaonkar AA, Al-Kali A, Gangat N, Tefferi A, Alkhateeb H, Garcia-Manero G, Komrokji RS, Ali NA, Padron E, Montalban-Bravo G, Patnaik MM. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica. 2024 Oct.109(10):3419-3425. Pubmedid: [38899337](https://www.ncbi.nlm.nih.gov/pubmed/38899337). Pmcid: PMC11443373. 
    * Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, Récher C. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. Am J Hematol. 2024 Oct.99(10):1870-1876. Pubmedid: [38899566](https://www.ncbi.nlm.nih.gov/pubmed/38899566). 
    * Crisà E, Mora E, Germing U, Bally C, Diez Campelo M, Myllymäki M, Jädersten M, Komrokji R, Platzbecker U, Haase D, Hofmann WK, Al Ali NH, Barraco D, Bargay JJ, Bernal T, López Cadenas F, Calvisi A, Capodanno I, Cerrano M, Ciancia R, Crugnola M, Kündgen A, Finelli C, Fozza C, Frairia C, Freja E, Ganster C, Kubasch AS, Jimenez MJ, Latagliata R, Hernandez Mohedo F, Molero A, Vara Pampliega M, Perez CA, Pietrantuono G, Poloni A, Pomares H, Recasens V, Rüfer A, Signori A, Hellstrom-Lindberg E, Fenaux P, Sanz G, Santini V. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study. Leukemia. 2024 Oct.38(10):2259-2265. Pubmedid: [39103678](https://www.ncbi.nlm.nih.gov/pubmed/39103678). 
    * Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al-Ali N, Xicoy B, Lopez F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Díaz Varela N, Platzbecker U, Haase DT, Díez-Campelo M, Della Porta MG, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion. Blood. 2024 Oct.144(16):1722-1731. Pubmedid: [39074355](https://www.ncbi.nlm.nih.gov/pubmed/39074355). 
    * Xie Z, Komrokji RS, Al-Ali N, Regelson A, Geyer S, Patel AA, Saygin C, Zeidan AM, Bewersdorf JP, Mendez LM, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung SS, Badar T, Foran JM, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana-Yi C, Osman AE, Dinner SN, Abaza Y, Taylor J, Chandhok NS, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Galli A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A. Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov.144(19):2033-2044. Pubmedid: [38996210](https://www.ncbi.nlm.nih.gov/pubmed/38996210). Pmcid: PMC11561536. 
    * Albanyan O, Elmariah H, Kalos D, Kim J, Faramand R, Sallman D, Mishra A, Sweet K, Perez L, Ochoa-Bayona J, Nieder M, Komrokji R, Lancet J, Fernandez H, Nishihori T, Pidala J, Anasetti C, Bejanyan N. Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Transplant Cell Ther. 2024 Nov.30(11):1090.e1-1090.e10. Pubmedid: [39147136](https://www.ncbi.nlm.nih.gov/pubmed/39147136). 
    * Komrokji RS, Lanino L, Ball S, Bewersdorf JP, Marchetti M, Maggioni G, Travaglino E, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Diez-Campelo M, Singh A, Jain AG, Aguirre LE, Tinsley-Vance SM, Schwabkey ZI, Chan O, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, Lancet J, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sweet K, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Sauta E, D'Amico S, Asti G, Castellani G, Delleani M, Campagna A, Borate UM, Sanz G, Efficace F, Gore SD, Kim TK, Daver N, Garcia-Manero G, Rozman M, Orfao A, Wang SA, Foucar MK, Germing U, Haferlach T, Scheinberg P, Miyazaki Y, Iastrebner M, Kulasekararaj A, Cluzeau T, Kordasti S, van de Loosdrecht AA, Ades L, Zeidan AM, Della Porta MG. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol. 2024 Nov.11(11):e862-e872. Pubmedid: [39393368](https://www.ncbi.nlm.nih.gov/pubmed/39393368). 
    * Efficace F, Buckstein R, Abel GA, Giesinger JM, Fenaux P, Bewersdorf JP, Brunner AM, Bejar R, Borate U, DeZern AE, Greenberg P, Roboz GJ, Savona MR, Sparano F, Boultwood J, Komrokji R, Sallman DA, Xie Z, Sanz G, Carraway HE, Taylor J, Nimer SD, Della Porta MG, Santini V, Stahl M, Platzbecker U, Sekeres MA, Zeidan AM. Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS). Hemasphere. 2024 May.8(5):e69. Pubmedid: [38774655](https://www.ncbi.nlm.nih.gov/pubmed/38774655). Pmcid: PMC11106800. 
    * Gregorio C, Spreafico M, D'Amico S, Sauta E, Asti G, Lanino L, Tentori CA, Platzbecker U, Haferlach T, Diez-Campelo M, Fenaux P, Komrokji R, Della Porta MG, Ieva F. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation. JCO Clin Cancer Inform. 2024 May.8:e2300205. Pubmedid: [38723213](https://www.ncbi.nlm.nih.gov/pubmed/38723213). 
    * Chan O, Al Ali NH, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini MO, Song J, Yun S, Talati C, Kuykendall AT, Padron E, Walker AR, Roboz GJ, Desai P, Sallman DA, Sweet KL, Komrokji RS, Lancet JE. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv. 2024 Mar.8(5):1075-1083. Pubmedid: [38170740](https://www.ncbi.nlm.nih.gov/pubmed/38170740). Pmcid: PMC10907389. 
    * Kuykendall AT, Ball S, Mora B, Mo Q, Al Ali N, Maffioli M, Auteri G, Mazzoni C, Palumbo GA, Duminuco A, Longo A, Elli EM, Passamonti F, Palandri F, Komrokji R. Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib. JCO Precis Oncol. 2024 Mar.8:e2300593. Pubmedid: [38484210](https://www.ncbi.nlm.nih.gov/pubmed/38484210). Pmcid: PMC10954075. 
    * Jain AG, Gesiotto Q, Ball S, Nodzon L, Rodriguez A, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman DA, Lancet JE, Pinilla-Ibarz J, Sweet K. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Ann Hematol. 2024 Jun.103(6):1941-1945. Pubmedid: [38634915](https://www.ncbi.nlm.nih.gov/pubmed/38634915). Pmcid: PMC11090947. 
    * Chavez JC, Grajales A, Sandoval-Sus J, Turba E, Nodzon L, Uriepero-Palma A, Ammad-Ud-Din M, Sahakian E, Komrokji R, Sokol L, Locke FL, Shah B, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Bello C, Pinilla-Ibarz J. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis. Clin Lymphoma Myeloma Leuk. 2024 Jun.24(6):382-391.e2. Pubmedid: [38508880](https://www.ncbi.nlm.nih.gov/pubmed/38508880). 
    * Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024 Jul.109(7):2157-2164. Pubmedid: [38299605](https://www.ncbi.nlm.nih.gov/pubmed/38299605). Pmcid: PMC11215361. 
    * Vincelette ND, Yu X, Kuykendall AT, Moon J, Su S, Cheng CH, Sammut R, Razabdouski TN, Nguyen HV, Eksioglu EA, Chan O, Al Ali N, Patel PC, Lee DH, Nakanishi S, Ferreira RB, Hyjek E, Mo Q, Cory S, Lawrence HR, Zhang L, Murphy DJ, Komrokji RS, Lee D, Kaufmann SH, Cleveland JL, Yun S. Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis. Blood Cancer Discov. 2024 Jul.5(4):276-297. Pubmedid: [38713018](https://www.ncbi.nlm.nih.gov/pubmed/38713018). Pmcid: PMC11215389. 
    * Aguirre LE, Jain A, Ball S, Ali NA, Volpe VO, Tinsley-Vance S, Sallman D, Sweet K, Lancet J, Padron E, Yun S, Kuykendall A, Komrokji R. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes. Clin Lymphoma Myeloma Leuk. 2024 Jul.24(7):459-467. Pubmedid: [38548563](https://www.ncbi.nlm.nih.gov/pubmed/38548563). 
    * Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, Díez-Campelo M, Valcárcel D, Illmer T, Jonášová A, Bělohlávková P, Sherman LJ, Berry T, Dougherty S, Shah S, Xia Q, Sun L, Wan Y, Huang F, Ikin A, Navada S, Feller F, Komrokji RS, Zeidan AM. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Jan.403(10423):249-260. Pubmedid: [38048786](https://www.ncbi.nlm.nih.gov/pubmed/38048786). 
    * Horvat NP, Abdallah EF, Xie Z, Al Ali N, Yun S, Walker A, Padron E, Sallman D, Chan O, Lancet J, Komrokji R, Kuykendall AT. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Ann Hematol. 2024 Jan.103(1):117-123. Pubmedid: [38030891](https://www.ncbi.nlm.nih.gov/pubmed/38030891). 
    * Tinsley-Vance SM, Mason TM, Komrokji RS. An integrative review of cancer-related cachexia and sarcopenia: A different focus in malignant hematology. Health Sci Rev (Oxf). 2024 Dec.13. Pubmedid: [39802938](https://www.ncbi.nlm.nih.gov/pubmed/39802938). Pmcid: PMC11720849. 
    * Aakash F, Gisriel SD, Zeidan AM, Bennett JM, Bejar R, Bewersdorf JP, Borate UM, Boultwood J, Brunner AM, Buckstein R, Carraway H, Churpek JE, Daver NG, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Garcia-Manero G, Gore SD, Greenberg PL, Griffiths EA, Halene S, Hourigan CS, Kim TK, Kim N, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Platzbecker U, Della Porta MG, Roboz GJ, Sallman DA, Santini V, Sanz G, Savona MR, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Wei AH, Zhuoer X, Xu ML, Hasserjian RP, Loghavi S. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Mod Pathol. 2024 Dec.37(12):100615. Pubmedid: [39322118](https://www.ncbi.nlm.nih.gov/pubmed/39322118). 
    * Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A, Savevski V, Santoro A, Al Ali N, Sallman D, Sole F, Garcia-Manero G, Germing U, Kroger N, Kordasti S, Santini V, Sanz G, Kern W, Platzbecker U, Diez-Campelo M, Maciejewski JP, Ades L, Fenaux P, Haferlach T, Zeidan AM, Castellani G, Komrokji R, Ieva F, Della Porta MG. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2024 Aug.42(24):2873-2886. Pubmedid: [38723212](https://www.ncbi.nlm.nih.gov/pubmed/38723212). Pmcid: PMC11328926. 
    * Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, Foran JM, Badar T, Khera N, Shah M, Hiwase D, Padron E, Sallman DA, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Brit J Haematol. 2024 Apr.204(4):1243-1248. Pubmedid: [38083865](https://www.ncbi.nlm.nih.gov/pubmed/38083865). 
    * Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol. 2023 Sep.10(9):e767-e776. Pubmedid: [37572683](https://www.ncbi.nlm.nih.gov/pubmed/37572683). 
    * Mascarenhas J, Migliaccio AR, Kosiorek H, Bhave R, Palmer J, Kuykendall A, Mesa R, Rampal RK, Gerds AT, Yacoub A, Pettit K, Talpaz M, Komrokji R, Kremyanskaya M, Gonzalez A, Fabris F, Johnson K, Dougherty M, McGovern E, Arango Ossa J, Domenico D, Farnoud N, Weinberg RS, Kong A, Najfeld V, Vannucchi AM, Arciprete F, Zingariello M, Falchi M, Salama ME, Mead-Harvey C, Dueck A, Varricchio L, Hoffman R. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis. Clin Cancer Res. 2023 Sep.29(18):3622-3632. Pubmedid: [37439808](https://www.ncbi.nlm.nih.gov/pubmed/37439808). Pmcid: PMC10502472. 
    * Li X, Hoogland AI, Small BJ, Crowder SL, Gonzalez BD, Oswald LB, Sleight AG, Nguyen N, Lorona NC, Damerell V, Komrokji KR, Mooney K, Playdon MC, Ulrich CM, Li CI, Shibata D, Toriola AT, Ose J, Peoples AR, Siegel EM, Bower JE, Schneider M, Gigic B, Figueiredo JC, Jim HSL. Trajectories and risk factors of fatigue following colorectal cancer diagnosis. Colorectal Dis. 2023 Oct.25(10):2054-2063. Pubmedid: [37700526](https://www.ncbi.nlm.nih.gov/pubmed/37700526). 
    * Jain AG, Ball S, Aguirre LE, Tobon KA, Chan O, Padron E, Kuykendall A, Komrokji R, Sallman D, Lancet JE, Sweet K. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2023 Oct.23(10):e315-e322. Pubmedid: [37558530](https://www.ncbi.nlm.nih.gov/pubmed/37558530). 
    * Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 Nov.41(31):4893-4904. Pubmedid: [37703506](https://www.ncbi.nlm.nih.gov/pubmed/37703506). Pmcid: PMC10617926. 
    * Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein R, Miteva D, Keeperman K, Holot N, Nadal JA, Lai Y, Vodala S, Rosettani B, Giuseppi AC, Yucel A, Fenaux P. Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 2023 Nov.37(11):2314-2318. Pubmedid: [37752285](https://www.ncbi.nlm.nih.gov/pubmed/37752285). Pmcid: PMC10624606. 
    * Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023 Nov.62:101128. Pubmedid: [37704469](https://www.ncbi.nlm.nih.gov/pubmed/37704469). 
    * Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 May.41(15):2815-2826. Pubmedid: [36888930](https://www.ncbi.nlm.nih.gov/pubmed/36888930). 
    * Aguirre LE, Sallman DA, Stone R, Komrokji RS. Updates in Risk Stratification in Myelodysplastic Syndromes. Cancer J. 2023 May.29(3):138-142. Pubmedid: [37195769](https://www.ncbi.nlm.nih.gov/pubmed/37195769). 
    * Tinsley-Vance SM, Ali NA, Ball S, Aguirre LE, Jain AG, Hussaini MO, Chan O, Kuykendall A, Sweet K, Lancet J, Padron E, Sallman DA, Komrokji RS. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes. Clin Lymphoma Myeloma Leuk. 2023 May.23(5):355-359. Pubmedid: [36813626](https://www.ncbi.nlm.nih.gov/pubmed/36813626). Pmcid: PMC10121764. 
    * Xie Z, Chen EC, Mendez LM, Komrokji R, Zeidan AM. Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms. Cancer J. 2023 May.29(3):130-137. Pubmedid: [37195768](https://www.ncbi.nlm.nih.gov/pubmed/37195768). 
    * Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: [36624015](https://www.ncbi.nlm.nih.gov/pubmed/36624015). 
    * Volpe VO, Garcia-Manero G, Komrokji RS. SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):168-177. Pubmedid: [36682988](https://www.ncbi.nlm.nih.gov/pubmed/36682988). 
    * Gangat N, Kuykendall AT, Al Ali NH, Goel S, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna K, Mangaonkar AA, Litzow MR, Hogan WJ, Shah MV, Patnaik MM, Pardanani AD, Komrokji RS, Tefferi A. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival. Blood Adv. 2023 Jun.7(12):2694-2698. Pubmedid: [36780345](https://www.ncbi.nlm.nih.gov/pubmed/36780345). Pmcid: PMC10333736. 
    * Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski DT, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore SD, List AF, Kuchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Adv. 2023 Jun.7(12):2709-2714. Pubmedid: [36260702](https://www.ncbi.nlm.nih.gov/pubmed/36260702). Pmcid: PMC10333740. 
    * Sekeres MA, Kim N, DeZern AE, Norsworthy KJ, Garcia JS, de Claro RA, Theoret MR, Jen EY, Ehrlich LA, Zeidan AM, Komrokji RS. Considerations for Drug Development in Myelodysplastic Syndromes. Clin Cancer Res. 2023 Jul.29(14):2573-2579. Pubmedid: [36688922](https://www.ncbi.nlm.nih.gov/pubmed/36688922). Pmcid: PMC10349686. 
    * Komrokji RS, Aguirre LE, Al-Ali N, Chan O, Xie Z, Kuykendall AT, Sweet KL, Lancet JE, Padron E, Sallman DA. Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Adv. 2023 Jul.7(14):3677-3679. Pubmedid: [37058483](https://www.ncbi.nlm.nih.gov/pubmed/37058483). Pmcid: PMC10365940. 
    * Tomlinson B, de Lima M, Cogle CR, Thompson MA, Grinblatt DL, Pollyea DA, Komrokji RS, Roboz GJ, Savona MR, Sekeres MA, Abedi M, Garcia-Manero G, Kurtin SE, Maciejewski JP, Patel JL, Revicki DA, George TI, Flick ED, Kiselev P, Louis CU, DeGutis IS, Nifenecker M, Erba HP, Steensma DP, Scott BL. Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care. Transplant Cell Ther. 2023 Jul.29(7):460.e1-460.e9. Pubmedid: [37086851](https://www.ncbi.nlm.nih.gov/pubmed/37086851). 
    * DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg HJ, Zhang L, Gore SD, Al Baghdadi T, Maciejewski JP, Liu JJ, Padron E, Komrokji RS, Saber W, Abel GA, Kroft SH, Harrington AM, Grimes T, Reed HHV, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions. Blood Adv. 2023 Jul.7(14):3749-3759. Pubmedid: [36947201](https://www.ncbi.nlm.nih.gov/pubmed/36947201). Pmcid: PMC10368770. 
    * Abel GA, Hebert D, Lee C, Rollison DE, Gillis N, Komrokji RS, Foran JM, Liu JJ, Al Baghdadi T, Deeg HJ, Gore SD, Saber W, Wilson SH, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood Adv. 2023 Jul.7(14):3506-3515. Pubmedid: [37146263](https://www.ncbi.nlm.nih.gov/pubmed/37146263). Pmcid: PMC10362255. 
    * Aguirre LE, Al Ali N, Sallman DA, Ball S, Jain AG, Chan O, Tinsley-Vance SM, Kuykendall A, Sweet K, Lancet JE, Padron E, Komrokji RS. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023 Jul.37(7):1530-1539. Pubmedid: [37147425](https://www.ncbi.nlm.nih.gov/pubmed/37147425). 
    * Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. 2023 Jul.402(10399):373-385. Pubmedid: [37311468](https://www.ncbi.nlm.nih.gov/pubmed/37311468). 
    * Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Rev. 2023 Jul.60:101072. Pubmedid: [36934059](https://www.ncbi.nlm.nih.gov/pubmed/36934059). 
    * Komrokji RS, Aguirre LE, Al-Ali N, Hussaini MO, Sallman DA, Rollison DE, Padron E. U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes. Blood Adv. 2023 Jan.7(1):1-8. Pubmedid: [36129843](https://www.ncbi.nlm.nih.gov/pubmed/36129843). Pmcid: PMC9813529. 
    * Ball S, Aguirre LE, Jain AG, Ali NA, Tinsley SM, Chan O, Kuykendall AT, Sweet K, Lancet JE, Sallman DA, Hussaini MO, Padron E, Komrokji RS. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients. Leuk Res. 2023 Jan.124:106999. Pubmedid: [36542963](https://www.ncbi.nlm.nih.gov/pubmed/36542963). 
    * Germing U, Fenaux P, Platzbecker U, Buckstein R, Santini V, Díez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji RS, Zeidan AM, Garcia-Manero G. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study. Ann Hematol. 2023 Feb.102(2):311-321. Pubmedid: [36635381](https://www.ncbi.nlm.nih.gov/pubmed/36635381). Pmcid: PMC9889415. 
    * Gangat N, Komrokji RS, Tefferi A. Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective. Am J Hematol. 2023 Feb.98(2):225-228. Pubmedid: [36377194](https://www.ncbi.nlm.nih.gov/pubmed/36377194). 
    * Patel PC, Ball S, Jain AG, Wang C, Hussaini MO, Aguirre LE, Chan O, Yun S, Kuykendall A, Padron E, Sweet K, Lancet JE, Komrokji RS, Sallman DA. Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia. Am J Hematol. 2023 Dec.98(12):E360-E363. Pubmedid: [37705256](https://www.ncbi.nlm.nih.gov/pubmed/37705256). 
    * Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, Palandri F, Iurlo A, De Stefano V, Kiladjian JJ, Elli EM, Polverelli N, Gotlib J, Albano F, Silver RT, Benevolo G, Ross DM, Devos T, Borsani O, Barbui T, Porta MGD, Bertù L, Komrokji R, Vannucchi AM, Passamonti F. Incidence of blast phase in myelofibrosis according to anemia severity. EJHaem. 2023 Aug.4(3):679-689. Pubmedid: [37601878](https://www.ncbi.nlm.nih.gov/pubmed/37601878). Pmcid: PMC10435699. 
    * Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. Clin Cancer Res. 2023 Aug.29(15):2919-2932. Pubmedid: [37223910](https://www.ncbi.nlm.nih.gov/pubmed/37223910). Pmcid: PMC10524644. 
    * Mangaonkar AA, Swoboda DM, Lasho TL, Finke C, Ketterling RP, Reichard KK, Komrokji R, Padron E, Patnaik MM. Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS). Leuk Res. 2023 Aug.131:107340. Pubmedid: [37356165](https://www.ncbi.nlm.nih.gov/pubmed/37356165). 
    * Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia. 2023 Aug.37(8):1753-1756. Pubmedid: [37422593](https://www.ncbi.nlm.nih.gov/pubmed/37422593). 
    * Waksal JA, Bruedigam C, Komrokji RS, Jamieson CHM, Mascarenhas JO. Telomerase-targeted therapies in myeloid malignancies. Blood Adv. 2023 Aug.7(16):4302-4314. Pubmedid: [37216228](https://www.ncbi.nlm.nih.gov/pubmed/37216228). Pmcid: PMC10424149. 
    * Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol. 2023 Apr.98(4):E76-E79. Pubmedid: [36655582](https://www.ncbi.nlm.nih.gov/pubmed/36655582). 
    * Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, Roboz GJ, Sweet K, Miller C, Wennborg A, Hickman DK, Kanagal-Shamanna R, Kantarjian H, Lancet J, Komrokji R, Attar EC, Sallman DA. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr.10(4):e272-e283. Pubmedid: [36990622](https://www.ncbi.nlm.nih.gov/pubmed/36990622). 
    * Komrokji R, Al Ali N, Chan O, Sweet K, Kuykendall A, Lancet J, Padron E, Sallman DA. IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy. Haematologica. 2023 Apr.108(4):1168-1172. Pubmedid: [36420802](https://www.ncbi.nlm.nih.gov/pubmed/36420802). Pmcid: PMC10071110. 
    * Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen DT, Buckstein RJ, Brunner AM, Carraway HE, Daver NG, Díez-Campelo M, de Witte TM, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner MC, Komrokji RS, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz GF, Scheinberg P, Stauder R, Van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023 Apr.141(17):2047-2061. Pubmedid: [36724453](https://www.ncbi.nlm.nih.gov/pubmed/36724453). 
    * Robin M, de Wreede LC, Padron E, Bakunina K, Fenaux P, Koster L, Nazha A, Beelen DW, Rampal RK, Sockel K, Komrokji RS, Gagelmann N, Eikema DJ, Radujkovic A, Finke J, Potter V, Killick S, Legrand-Izadifar F, Solary E, Broom A, Garcia-Manero G, Rizzoli V, Hayden P, Patnaik MM, Onida F, Yakoub-Agha I, Itzykson RA. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022 Sep.140(12):1408-1418. Pubmedid: [35667047](https://www.ncbi.nlm.nih.gov/pubmed/35667047). 
    * Moyo TK, Mendler JH, Itzykson R, Kishtagari A, Solary E, Seegmiller AC, Gerds AT, Ayers GD, Dezern AE, Nazha A, Valent P, van de Loosdrecht AA, Onida F, Pleyer L, Cirici BX, Tibes R, Geissler K, Komrokji RS, Zhang J, Germing U, Steensma DP, Wiseman DH, Pfeilstöecker M, Elena C, Cross NCP, Kiladjian JJ, Luebbert M, Mesa RA, Montalban-Bravo G, Sanz GF, Platzbecker U, Patnaik MM, Padron E, Santini V, Fenaux P, Savona MR. The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. BMC Cancer. 2022 Sep.22(1):1013. Pubmedid: [36153475](https://www.ncbi.nlm.nih.gov/pubmed/36153475). Pmcid: PMC9509596. 
    * Radakovich N, Sallman DA, Buckstein R, Brunner A, Dezern A, Mukerjee S, Komrokji R, Al-Ali N, Shreve J, Rouphail Y, Parmentier A, Mamedov A, Siddiqui M, Guan Y, Kuzmanovic T, Hasipek M, Jha B, Maciejewski JP, Sekeres MA, Nazha A. A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. iScience. 2022 Oct.25(10):104931. Pubmedid: [36157589](https://www.ncbi.nlm.nih.gov/pubmed/36157589). Pmcid: PMC9490588. 
    * Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, De Stefano V, Caramella M, Salmoiraghi S, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Ruggeri M, Silver RT, Albano F, Benevolo G, Ross DM, Della Porta MG, Devos T, Rotunno G, Komrokji RS, Casetti IC, Merli M, Brociner M, Caramazza D, Auteri G, Barbui T, Cattaneo D, Bertù L, Arcaini L, Vannucchi AM, Passamonti F. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. Leukemia. 2022 Oct.36(10):2453-2460. Pubmedid: [36042316](https://www.ncbi.nlm.nih.gov/pubmed/36042316). 
    * Kuykendall AT, Mo Q, Sallman DA, Ali NA, Chan O, Yun S, Sweet KL, Padron E, Lancet JE, Komrokji RS. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer. 2022 Oct.128(19):3495-3501. Pubmedid: [35942592](https://www.ncbi.nlm.nih.gov/pubmed/35942592). 
    * Lee D, Jain AG, Deutsch Y, Eatrides J, Chan O, Padron E, Kuykendall A, Komrokji R, Lancet J, Sallman D, Talati C, Sweet K. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2022 Oct.22(10):774-779. Pubmedid: [35760672](https://www.ncbi.nlm.nih.gov/pubmed/35760672). 
    * Komrokji RS, Singh AM, Ali NA, Chan O, Padron E, Sweet K, Kuykendall A, Lancet JE, Sallman DA. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022 Nov.12(11):148. Pubmedid: [36329025](https://www.ncbi.nlm.nih.gov/pubmed/36329025). Pmcid: PMC9633639. 
    * Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, Döhner H, Falini B, Garcia-Manero G, Haferlach T, Hellström-Lindberg E, Kim AS, Klco JM, Komrokji RS, Loh ML, Loghavi S, Mullighan CG, Ogawa S, Tefferi A, Papaemmanuil E, Reiter A, Ross DM, Savona MR, Shimamura A, Skoda RC, Sole F, Stone RM, Orazi A, Walter MJ, Wu D, Ebert BL, Cazzola M. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 Nov.140(21):2228-2247. Pubmedid: [36130297](https://www.ncbi.nlm.nih.gov/pubmed/36130297). 
    * Ferrall-Fairbanks MC, Dhawan A, Johnson B, Newman H, Volpe V, Letson C, Ball M, Hunter AM, Balasis ME, Kruer T, Ben-Crentsil NA, Kroeger JL, Balderas R, Komrokji RS, Sallman DA, Zhang J, Bejar R, Altrock PM, Padron E. Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discov. 2022 Nov.3(6):536-553. Pubmedid: [36053528](https://www.ncbi.nlm.nih.gov/pubmed/36053528). Pmcid: PMC9627238. 
    * Ball S, Knepper TC, Deutsch YE, Samra W, Watts JM, Bradley TJ, Chan O, Hussaini MO, Zhang L, Sweet KL, Kuykendall AT, Talati C, Padron E, Komrokji RS, Lancet JE, Sallman DA. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer. 2022 Nov.128(21):3880-3887. Pubmedid: [36107670](https://www.ncbi.nlm.nih.gov/pubmed/36107670). 
    * Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, Rüter B, Burkard U, Osswald A, Foran JM. A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome. Haematologica. 2022 Nov.107(11):2742-2747. Pubmedid: [35734924](https://www.ncbi.nlm.nih.gov/pubmed/35734924). Pmcid: PMC9614517. 
    * Brunner AM, Gavralidis A, Ali NA, Hunter A, Komrokji R, Zeidan A, Sallman DA. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS). Blood Cancer J. 2022 Nov.12(11):153. Pubmedid: [36379923](https://www.ncbi.nlm.nih.gov/pubmed/36379923). Pmcid: PMC9666661. 
    * Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma A, Mufti Obe GJ, Buckstein RJ, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood. 2022 Nov.140(20):2170-2174. Pubmedid: [35797468](https://www.ncbi.nlm.nih.gov/pubmed/35797468). 
    * Jain AG, Zhang L, Bennett JM, Komrokji R. Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update. Ann Lab Med. 2022 May.42(3):299-305. Pubmedid: [34907099](https://www.ncbi.nlm.nih.gov/pubmed/34907099). Pmcid: PMC8677477. 
    * Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Ali NHA, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022 May.107(5):1189-1192. Pubmedid: [35142154](https://www.ncbi.nlm.nih.gov/pubmed/35142154). Pmcid: PMC9052897. 
    * Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol. 2022 May.40(15):1671-1680. Pubmedid: [35180010](https://www.ncbi.nlm.nih.gov/pubmed/35180010). Pmcid: PMC9113204. 
    * Ball S, Jain AG, Aguirre LE, Al Ali N, Zhang Y, Chan O, Kuykendall AT, Sweet KL, Lancet JE, Swoboda DM, Padron E, Komrokji RS, Sallman DA. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. Am J Hematol. 2022 May.97(5):E185-E188. Pubmedid: [35179241](https://www.ncbi.nlm.nih.gov/pubmed/35179241). 
    * Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, Díez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, Verma A. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia. 2022 May.36(5):1432-1435. Pubmedid: [35220402](https://www.ncbi.nlm.nih.gov/pubmed/35220402). Pmcid: PMC9061284. 
    * Wang C, McGraw KL, McLemore AF, Komrokji R, Basiorka AA, Al Ali N, Lancet JE, Padron E, Kosmider O, Fontenay M, Fenaux P, List AF, Sallman DA. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. Haematologica. 2022 Mar.107(3):737-739. Pubmedid: [34320786](https://www.ncbi.nlm.nih.gov/pubmed/34320786). Pmcid: PMC8883562. 
    * Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji RS, Cattaneo D, Della Porta MG, Giorgino T, Bertù L, Brociner M, Kuykendall AT, Passamonti F. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022 Mar.6(6):1855-1864. Pubmedid: [35130339](https://www.ncbi.nlm.nih.gov/pubmed/35130339). Pmcid: PMC8941454. 
    * Ball S, Komrokji RS, Sallman DA. Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile. Leuk Lymphoma. 2022 Jun.63(6):1281-1291. Pubmedid: [34933652](https://www.ncbi.nlm.nih.gov/pubmed/34933652). 
    * Walsh C, Hunter A, Lasho T, Finke C, Ketterling R, Komrokji R, Tefferi A, Mangaonkar A, Howard M, Gangat N, Al-Kali A, Ali NA, Padron E, Patnaik MM. Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia. 2022 Jun.36(6):1693-1696. Pubmedid: [35351982](https://www.ncbi.nlm.nih.gov/pubmed/35351982). 
    * Castillo Tokumori F, Al Ali N, Chan O, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e521-e525. Pubmedid: [35241387](https://www.ncbi.nlm.nih.gov/pubmed/35241387). 
    * Chan O, Ali NA, Sallman D, Padron E, Lancet J, Komrokji R. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Clin Lymphoma Myeloma Leuk. 2022 Jul.22(7):e467-e476. Pubmedid: [35101379](https://www.ncbi.nlm.nih.gov/pubmed/35101379). 
    * Mascarenhas J, Harrison CN, Kiladjian JJ, Komrokji RS, Koschmieder S, Vannucchi AM, Berry T, Redding D, Sherman L, Dougherty S, Peng L, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Verstovsek S. Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. Future Oncol. 2022 Jul.18(22):2393-2402. Pubmedid: [35510486](https://www.ncbi.nlm.nih.gov/pubmed/35510486). 
    * Kuykendall AT, Sun L, Mascarenhas J, Kiladjian JJ, Vannucchi AM, Wang J, Xia Q, Zhu E, Feller F, Rizo A, Bussolari J, Wan Y, Komrokji R. Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data. Ann Hematol. 2022 Jan.101(1):139-146. Pubmedid: [34622316](https://www.ncbi.nlm.nih.gov/pubmed/34622316). 
    * Garcia-Manero G, Mufti Obe GJ, Fenaux P, Buckstein RJ, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. 2022 Jan.139(4):624-629. Pubmedid: [34758066](https://www.ncbi.nlm.nih.gov/pubmed/34758066). Pmcid: PMC8796653. 
    * Volpe VO, Garcia-Manero G, Komrokji RS. Myelodysplastic Syndromes: A New Decade. Clin Lymphoma Myeloma Leuk. 2022 Jan.22(1):1-16. Pubmedid: [34544674](https://www.ncbi.nlm.nih.gov/pubmed/34544674). 
    * Komrokji R, Melody M, Al Ali N, Chan O, Klimek V, Ball BJ, Sekeres MA, Lucas G, Maciejewski JP, Sallman DA, Padron E, Kuykendall A, Lasho T, Al-Kali A, Naqvi K, Steensma DP, Garcia-Manero G, Patnaik MM. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2022 Jan.63(1):199-204. Pubmedid: [34448437](https://www.ncbi.nlm.nih.gov/pubmed/34448437). 
    * Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, Begna KH, Pardanani A, Al Ali NH, Talati C, Sallman D, Padron E, Patnaik MM, Tefferi A, Komrokji R. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer J. 2022 Feb.12(2):26. Pubmedid: [35105856](https://www.ncbi.nlm.nih.gov/pubmed/35105856). Pmcid: PMC8807827. 
    * Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia. 2022 Dec.36(12):2939-2946. Pubmedid: [36266326](https://www.ncbi.nlm.nih.gov/pubmed/36266326). 
    * Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia. 2022 Dec.36(12):2934-2938. Pubmedid: [36335264](https://www.ncbi.nlm.nih.gov/pubmed/36335264). 
    * Volpe VO, Al Ali N, Chan O, Padron E, Sallman DA, Kuykendall A, Sweet K, Lancet JE, Komrokji RS. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. Brit J Haematol. 2022 Aug.198(4):713-720. Pubmedid: [35751140](https://www.ncbi.nlm.nih.gov/pubmed/35751140). 
    * Swoboda DM, Kanagal-Shamanna R, Brunner AM, Cluzeau T, Chan O, Al Ali N, Montalban-Bravo G, Gesiotto QJ, Gavralidis A, Hunter AM, Lee JH, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, Hussaini M, Song J, Garcia-Manero G, Komrokji RS, Sallman DA. Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia. 2022 Apr.36(4):1189-1192. Pubmedid: [34975158](https://www.ncbi.nlm.nih.gov/pubmed/34975158). 
    * Komrokji RS, Volpe VO, Chan O, Al Ali NH, Swoboda DM, Kuykendall AT, Padron E, Sallman DA. Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes. Blood. 2021 Sep.138(11):989-992. Pubmedid: [34036300](https://www.ncbi.nlm.nih.gov/pubmed/34036300). 
    * Cluzeau T, Loschi M, Fenaux P, Komrokji R, Sallman DA. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. Int J Mol Sci. 2021 Sep.22(18). Pubmedid: [34576266](https://www.ncbi.nlm.nih.gov/pubmed/34576266). Pmcid: PMC8471083. 
    * Castillo Tokumori F, Komrokji R, Kuykendall AT. Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera. Expert Opin Emerg Drugs. 2021 Sep.26(3):209-218. Pubmedid: [34139920](https://www.ncbi.nlm.nih.gov/pubmed/34139920). 
    * Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 Sep.39(26):2881-2892. Pubmedid: [34138638](https://www.ncbi.nlm.nih.gov/pubmed/34138638). 
    * Hunter AM, Al Ali N, Mai A, Shah S, Swoboda DM, Kuykendall A, Talati C, Sweet KL, Sallman DA, Lancet JE, Komrokji RS, Padron E. Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy. Leuk Res. 2021 Oct.109:106640. Pubmedid: [34144312](https://www.ncbi.nlm.nih.gov/pubmed/34144312). 
    * Hunter AM, Newman H, DeZern AE, Steensma DP, Niyongere S, Roboz GJ, Mo Q, Chan O, Gerds A, Sallman DA, Dominguez-Viqueira W, Letson C, Balasis ME, Ball M, Kruer T, Zhang H, Lancet JE, List AF, Sekeres MA, Komrokji RS, Padron E. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia. Clin Cancer Res. 2021 Nov.27(22):6095-6105. Pubmedid: [34253584](https://www.ncbi.nlm.nih.gov/pubmed/34253584). Pmcid: PMC8595542. 
    * Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, Maciejewski JP, Haferlach T, Sekeres MA. Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. J Clin Oncol. 2021 Nov.39(33):3737-3746. Pubmedid: [34406850](https://www.ncbi.nlm.nih.gov/pubmed/34406850). Pmcid: PMC8601291. 
    * Komrokji R, Al Ali N, Padron E, Lancet J, Nazha A, Steensma D, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Sallman D. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leuk Lymphoma. 2021 Nov.62(11):2762-2767. Pubmedid: [34114922](https://www.ncbi.nlm.nih.gov/pubmed/34114922). 
    * Radakovich N, Meggendorfer M, Malcovati L, Hilton CB, Sekeres MA, Shreve J, Rouphail Y, Walter W, Hutter S, Galli A, Pozzi S, Elena C, Padron E, Savona MR, Gerds AT, Mukherjee S, Nagata Y, Komrokji RS, Jha BK, Haferlach C, Maciejewski JP, Haferlach T, Nazha A. A geno-clinical decision model for the diagnosis of myelodysplastic syndromes. Blood Adv. 2021 Nov.5(21):4361-4369. Pubmedid: [34592765](https://www.ncbi.nlm.nih.gov/pubmed/34592765). Pmcid: PMC8579270. 
    * Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021 May.39(14):1584-1594. Pubmedid: [33449813](https://www.ncbi.nlm.nih.gov/pubmed/33449813). Pmcid: PMC8099410. 
    * Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, Sallman DA, Komrokji R, Walter-Petrich A, Chevret S, Ades L, Fenaux P. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol. 2021 May.39(14):1575-1583. Pubmedid: [33600210](https://www.ncbi.nlm.nih.gov/pubmed/33600210). Pmcid: PMC8099409. 
    * Zeidan AM, Komrokji RS, Brunner AM. TIM-3 pathway dysregulation and targeting in cancer. Expert Rev Anticancer Ther. 2021 May.21(5):523-534. Pubmedid: [33334180](https://www.ncbi.nlm.nih.gov/pubmed/33334180). 
    * Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. Leukemia. 2021 Mar.35(3):835-849. Pubmedid: [32595214](https://www.ncbi.nlm.nih.gov/pubmed/32595214). Pmcid: PMC7932916. 
    * Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 Mar.11(3):52. Pubmedid: [33677472](https://www.ncbi.nlm.nih.gov/pubmed/33677472). Pmcid: PMC7936977. 
    * List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman JK, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar TR, Artz AS, Schiffer CA, Litzow MR, Tallman MS. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. J Clin Oncol. 2021 Mar.39(9):1001-1009. Pubmedid: [33439748](https://www.ncbi.nlm.nih.gov/pubmed/33439748). Pmcid: PMC8274743. 
    * Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA. Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies. Clin Lymphoma Myeloma Leuk. 2021 Jun.21(6):421-424.e2. Pubmedid: [33583730](https://www.ncbi.nlm.nih.gov/pubmed/33583730). 
    * Patel JL, Abedi M, Cogle CR, Erba HP, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Kurtin SE, Maciejewski JP, Pollyea DA, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Steensma DP, Thompson MA, Dawn Flick E, Kiselev P, Louis CU, Nifenecker M, Swern AS, George TI. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. Int J Lab Hematol. 2021 Jun.43(3):426-432. Pubmedid: [33220019](https://www.ncbi.nlm.nih.gov/pubmed/33220019). Pmcid: PMC8247031. 
    * Swoboda DM, Ali NA, Chan O, Padron E, Kuykendall AT, Song J, Hussaini M, Talati C, Sweet K, Lancet JE, Sallman DA, Komrokji RS. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia. 2021 Jan.35(1):286-288. Pubmedid: [33132383](https://www.ncbi.nlm.nih.gov/pubmed/33132383). 
    * Schwabkey ZI, Al Ali N, Chan O, Sallman DA, Padron E, Kuykendall AT, Talati C, Sweet K, Lancet JE, Komrokji RS. Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clin Lymphoma Myeloma Leuk. 2021 Jan.21(1):e52-e56. Pubmedid: [33093008](https://www.ncbi.nlm.nih.gov/pubmed/33093008). 
    * Komrokji RS, Al Ali NH, Sallman D, Padron E, DeZern AE, Barnard J, Roboz GJ, Garcia-Manero G, List A, Steensma DP, Sekeres MA. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer Med. 2021 Jan.10(2):447-453. Pubmedid: [33350168](https://www.ncbi.nlm.nih.gov/pubmed/33350168). Pmcid: PMC7877342. 
    * Volpe VO, Komrokji RS. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?. Ther Adv Hematol. 2021 Jan.12. Pubmedid: [33505645](https://www.ncbi.nlm.nih.gov/pubmed/33505645). Pmcid: PMC7812395. 
    * Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Adv. 2021 Feb.5(4):1017-1028. Pubmedid: [33591325](https://www.ncbi.nlm.nih.gov/pubmed/33591325). Pmcid: PMC7903224. 
    * Oliva EN, Platzbecker U, Garcia-Manero G, Mufti GJ, Santini V, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P. Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. J Clin Med. 2021 Dec.11(1). Pubmedid: [35011768](https://www.ncbi.nlm.nih.gov/pubmed/35011768). Pmcid: PMC8745777. 
    * Aguirre LE, Komrokji R, Padron E. It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. Best Pract Res Clin Haematol. 2021 Dec.34(4):101325. Pubmedid: [34865697](https://www.ncbi.nlm.nih.gov/pubmed/34865697). 
    * Gajzer D, Logothetis CN, Sallman DA, Calon G, Babu A, Chan O, Vincelette ND, Volpe VO, Al Ali NH, Basra P, Talati C, Kuykendall AT, Mo Q, Padron E, Sweet K, Komrokji RS, Lancet JE, Yun S, Zhang L. MYC overexpression is associated with an early disease progression from MDS to AML. Leuk Res. 2021 Dec.111:106733. Pubmedid: [34749168](https://www.ncbi.nlm.nih.gov/pubmed/34749168). Pmcid: PMC8643343. 
    * Schwabkey Z, Al Ali N, Sallman D, Kuykendall A, Talati C, Sweet K, Lancet J, Padron E, Komrokji R. Impact of obesity on survival of patients with myelodysplastic syndromes. Hematology. 2021 Dec.26(1):393-397. Pubmedid: [34029507](https://www.ncbi.nlm.nih.gov/pubmed/34029507). 
    * Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Piérola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021 Dec.35(12):3542-3550. Pubmedid: [34172893](https://www.ncbi.nlm.nih.gov/pubmed/34172893). Pmcid: PMC8632688. 
    * Kuykendall AT, Komrokji RS. JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis. J Immunother Precis Oncol. 2021 Aug.4(3):129-141. Pubmedid: [35663107](https://www.ncbi.nlm.nih.gov/pubmed/35663107). Pmcid: PMC9138443. 
    * Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, Sallman DA. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2021 Apr.35(4):1145-1155. Pubmedid: [32728186](https://www.ncbi.nlm.nih.gov/pubmed/32728186). Pmcid: PMC7854836. 
    * Chan O, Komrokji RS. Luspatercept in the treatment of lower-risk myelodysplastic syndromes. Future Oncol. 2021 Apr.17(12):1473-1481. Pubmedid: [33511859](https://www.ncbi.nlm.nih.gov/pubmed/33511859). 
    * Kuykendall AT, Tokumori FC, Komrokji RS. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes. Hematol Oncol Clin North Am. 2021 Apr.35(2):337-352. Pubmedid: [33641873](https://www.ncbi.nlm.nih.gov/pubmed/33641873). 
    * Kuykendall AT, Komrokji R. What's in a Number? Examining the Prognostic and Predictive Importance of Platelet Count in Patients With Essential Thrombocythemia. J Natl Compr Canc Ne. 2020 Sep.18(9):1279-1284. Pubmedid: [32886905](https://www.ncbi.nlm.nih.gov/pubmed/32886905). 
    * Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, Komrokji RS. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clin Lymphoma Myeloma Leuk. 2020 Sep.20(9):e597-e605. Pubmedid: [32303488](https://www.ncbi.nlm.nih.gov/pubmed/32303488). 
    * Zhang Y, Varnadoe C, Tandon A, Forsyth P, Komrokji R, Sokol L. Myasthenia Gravis and Large Granular Lymphocytic Leukemia: a rare association. Leuk Res Rep. 2020 Oct.14:100226. Pubmedid: [33094093](https://www.ncbi.nlm.nih.gov/pubmed/33094093). Pmcid: PMC7568180. 
    * Komrokji RS, Ali NA, Sallman D, Padron E, Lancet J, Sokol L, Varnadoe C, Burnette PK, List A. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia. 2020 Nov.34(11):3097-3099. Pubmedid: [32565544](https://www.ncbi.nlm.nih.gov/pubmed/32565544). 
    * Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv. 2020 Nov.4(22):5716-5721. Pubmedid: [33216886](https://www.ncbi.nlm.nih.gov/pubmed/33216886). Pmcid: PMC7686903. 
    * Brierley CK, Zabor EC, Komrokji RS, DeZern AE, Roboz GJ, Brunner AM, Stone RM, Sekeres MA, Steensma DP. Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes. Cancer. 2020 Nov.126(21):4735-4743. Pubmedid: [32767690](https://www.ncbi.nlm.nih.gov/pubmed/32767690). 
    * Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, Sweet K, Lancet J, List A, Bennett JM, Komrokji R. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):324-328. Pubmedid: [32044274](https://www.ncbi.nlm.nih.gov/pubmed/32044274). 
    * Antelo G, Mangaonkar AA, Coltro G, Buradkar A, Lasho TL, Finke C, Carr R, Binder M, Gangat N, Al-Kali A, Elliott MA, King RL, Howard M, Melody ME, Hogan W, Litzow MR, Tefferi A, Fernandez-Zapico ME, Komrokji R, Patnaik MM. Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Brit J Haematol. 2020 May.189(3):e104-e108. Pubmedid: [32128785](https://www.ncbi.nlm.nih.gov/pubmed/32128785). 
    * Melody M, Kuykendall A, Sallman D, Al Ali N, Zhang L, Talati C, Padron E, Sweet K, Extermann M, List A, Lancet J, Komrokji R. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Clin Lymphoma Myeloma Leuk. 2020 May.20(5):312-315. Pubmedid: [32139296](https://www.ncbi.nlm.nih.gov/pubmed/32139296). 
    * Calleja A, Yun S, Moreilhon C, Karsenti JM, Gastaud L, Mannone L, Komrokji R, Ali NA, Dadone-Montaudie B, Robert G, Auberger P, Raynaud S, Sallman DA, Cluzeau T. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. Eur J Haematol. 2020 May.104(5):488-498. Pubmedid: [31990086](https://www.ncbi.nlm.nih.gov/pubmed/31990086). 
    * Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020 May.4(9):1965-1973. Pubmedid: [32384540](https://www.ncbi.nlm.nih.gov/pubmed/32384540). Pmcid: PMC7218417. 
    * Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, McLeod HL, Greene JN. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clin Pharmacol Ther. 2020 Mar.107(3):563-570. Pubmedid: [31549389](https://www.ncbi.nlm.nih.gov/pubmed/31549389). Pmcid: PMC7018540. 
    * Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J, Famulare C, Sallman D, Padron E, Kuykendall A, Lancet JE, Wang E, Tallman MS, Komrokji R, Sweet K. Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leuk Res. 2020 Jun.93:106367. Pubmedid: [32408060](https://www.ncbi.nlm.nih.gov/pubmed/32408060). Pmcid: PMC7771257. 
    * Badar T, Szabo A, Sallman D, Komrokji R, Lancet J, Padron E, Song J, Hussaini MO. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020 Jun.61(6):1418-1427. Pubmedid: [32013644](https://www.ncbi.nlm.nih.gov/pubmed/32013644). 
    * Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, Padron E, Komrokji RS. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2020 Jun.20(6):400-406.e2. Pubmedid: [32179032](https://www.ncbi.nlm.nih.gov/pubmed/32179032). Pmcid: PMC7771378. 
    * Pollyea DA, George TI, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, Grinblatt DL, Komrokji RS, Maciejewski JP, Revicki DA, Roboz GJ, Savona MR, Scott BL, Sekeres MA, Thompson MA, Kurtin SE, Louis CU, Nifenecker M, Flick ED, Swern AS, Kiselev P, Steensma DP, Erba HP. Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect® MDS/AML Disease Registry. EJHaem. 2020 Jul.1(1):58-68. Pubmedid: [35847712](https://www.ncbi.nlm.nih.gov/pubmed/35847712). Pmcid: PMC9176048. 
    * Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020 Jul.4(13):2866-2870. Pubmedid: [32589727](https://www.ncbi.nlm.nih.gov/pubmed/32589727). Pmcid: PMC7362378. 
    * Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres M, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase DT, Tuechler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg ES, Cazzola M. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020 Jul.136(2):157-170. Pubmedid: [32347921](https://www.ncbi.nlm.nih.gov/pubmed/32347921). Pmcid: PMC7362582. 
    * Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, Caramella M, Komrokji RS, Kiladjian JJ, Gotlib J, Iurlo A, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Albano F, Benevolo G, Cavalloni C, Uccella S, Accetta R, Siracusa C, Agnoli S, Merli M, Barbui T, Bertù L, Cazzola M, Vannucchi AM, Passamonti F. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. Am J Hematol. 2020 Jan.95(1):E1-E3. Pubmedid: [31588594](https://www.ncbi.nlm.nih.gov/pubmed/31588594). 
    * Talati C, Dhulipala VC, Extermann M, Al Ali N, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia. Haematologica. 2020 Jan.105(2):398-406. Pubmedid: [31073071](https://www.ncbi.nlm.nih.gov/pubmed/31073071). Pmcid: PMC7012500. 
    * Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2020 Jan.26(1):54-60. Pubmedid: [31636097](https://www.ncbi.nlm.nih.gov/pubmed/31636097). Pmcid: PMC7787346. 
    * Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. N Engl J Med. 2020 Jan.382(2):140-151. Pubmedid: [31914241](https://www.ncbi.nlm.nih.gov/pubmed/31914241). 
    * Verma A, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes. J Clin Invest. 2020 Feb.130(2):582-589. Pubmedid: [31961337](https://www.ncbi.nlm.nih.gov/pubmed/31961337). Pmcid: PMC6994157. 
    * Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, Ebert BL, Al-Ali N, Lancet JE, Cleveland JL, Padron E, List AF. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020 Dec.136(24):2812-2823. Pubmedid: [32730593](https://www.ncbi.nlm.nih.gov/pubmed/32730593). Pmcid: PMC7731792. 
    * Castillo-Tokumori F, Talati C, Al Ali N, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e956-e960. Pubmedid: [32778513](https://www.ncbi.nlm.nih.gov/pubmed/32778513). 
    * Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Komrokji R, Steensma D, Balleari E, Götze KS, Kotsianidis I, Guerci-Bresler A, Stamatoullas A, Sanz GF, Germing U, Fenaux P. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leuk Res. 2020 Dec.99:106472. Pubmedid: [33212326](https://www.ncbi.nlm.nih.gov/pubmed/33212326). 
    * Kuykendall AT, Horvat NP, Pandey G, Komrokji R, Reuther GW. Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis. Cancers (Basel). 2020 Aug.12(8). Pubmedid: [32823910](https://www.ncbi.nlm.nih.gov/pubmed/32823910). Pmcid: PMC7464183. 
    * Duong VH, Al Ali N, Zhang L, Padron E, Sallman D, Lancet JE, List AF, Komrokji RS. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. Leuk Lymphoma. 2020 Aug.61(8):1901-1907. Pubmedid: [32306798](https://www.ncbi.nlm.nih.gov/pubmed/32306798). 
    * Patnaik MM, Sallman DA, Mangaonkar A, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020 Aug.136(7):909-913. Pubmedid: [32294158](https://www.ncbi.nlm.nih.gov/pubmed/32294158). Pmcid: PMC7531999. 
    * Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug.7(8):e601-e612. Pubmedid: [32563283](https://www.ncbi.nlm.nih.gov/pubmed/32563283). Pmcid: PMC7302757. 
    * Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, Litzow MR, Komrokji RS, Erba HP, Appelbaum FR. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv. 2020 Apr.4(8):1683-1689. Pubmedid: [32330241](https://www.ncbi.nlm.nih.gov/pubmed/32330241). Pmcid: PMC7189292. 
    * Kis B, Mills M, Smith J, Choi J, Sagatys E, Komrokji R, Strosberg J, Kim RD. Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol. 2020 Apr.31(4):584-591. Pubmedid: [31471193](https://www.ncbi.nlm.nih.gov/pubmed/31471193). 
    * Badaat I, Mirza S, Padron E, Sallman D, Komrokji R, Song J, Hussaini MO. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome. J Clin Pathol. 2020 Apr.73(4):209-212. Pubmedid: [31771970](https://www.ncbi.nlm.nih.gov/pubmed/31771970). 
    * Komrokji RS. Luspatercept in Myelodysplastic Syndromes: Who and When?. Hematol Oncol Clin North Am. 2020 Apr.34(2):393-400. Pubmedid: [32089218](https://www.ncbi.nlm.nih.gov/pubmed/32089218). 
    * Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep.84:106194. Pubmedid: [31357093](https://www.ncbi.nlm.nih.gov/pubmed/31357093). Pmcid: PMC7375354. 
    * Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP. Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence. JCO Precis Oncol. 2019 Oct.3. Pubmedid: [31663066](https://www.ncbi.nlm.nih.gov/pubmed/31663066). Pmcid: PMC6818517. 
    * Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2019 Mar.19(3):157-161. Pubmedid: [30713125](https://www.ncbi.nlm.nih.gov/pubmed/30713125). 
    * Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019 Mar.3(6):922-933. Pubmedid: [30902805](https://www.ncbi.nlm.nih.gov/pubmed/30902805). Pmcid: PMC6436014. 
    * Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res. 2019 Jun.81:56-61. Pubmedid: [31030089](https://www.ncbi.nlm.nih.gov/pubmed/31030089). Pmcid: PMC7787349. 
    * Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Malloy M, Castro-Malaspina H, Giralt S, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis. Biol Blood Marrow Tr. 2019 Jun.25(6):1142-1151. Pubmedid: [30625392](https://www.ncbi.nlm.nih.gov/pubmed/30625392). Pmcid: PMC6918823. 
    * Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019 Jul.33(7):1747-1758. Pubmedid: [30635634](https://www.ncbi.nlm.nih.gov/pubmed/30635634). Pmcid: PMC6609480. 
    * Mirza AS, Yun S, Ali NA, Shin H, O'Neil JL, Elharake M, Schwartz D, Robinson K, Nowell E, Engle G, Badat I, Brimer T, Kuc A, Sequeira A, Mirza S, Sikaria D, Vera JD, Hackney N, Abusrur S, Jesurajan J, Kuang J, Patel S, Khalil S, Bhaskar S, Beard A, Abuelenen T, Ratnasamy K, Visweshwar N, Komrokji R, Jaglal M. Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience. Thromb J. 2019 Jul.17:13. Pubmedid: [31303864](https://www.ncbi.nlm.nih.gov/pubmed/31303864). Pmcid: PMC6604148. 
    * Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2019 Jan.60(1):246-249. Pubmedid: [29963936](https://www.ncbi.nlm.nih.gov/pubmed/29963936). 
    * Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019 Jan.33(1):205-216. Pubmedid: [30026572](https://www.ncbi.nlm.nih.gov/pubmed/30026572). Pmcid: PMC7787307. 
    * Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan.94(1):87-92. Pubmedid: [30390311](https://www.ncbi.nlm.nih.gov/pubmed/30390311). 
    * Smith BN, Savona M, Komrokji RS. Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Clin Lymphoma Myeloma Leuk. 2019 Jan.19(1):1-8. Pubmedid: [30555034](https://www.ncbi.nlm.nih.gov/pubmed/30555034). Pmcid: PMC7493410. 
    * McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. Brit J Haematol. 2019 Feb.184(3):450-455. Pubmedid: [29359794](https://www.ncbi.nlm.nih.gov/pubmed/29359794). Pmcid: PMC7771337. 
    * Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly A, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Sridharan A, Gueorguieva I, Girvan A, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Will B, Verma A. Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clin Cancer Res. 2019 Dec.25(23):6976-6985. Pubmedid: [31481511](https://www.ncbi.nlm.nih.gov/pubmed/31481511). 
    * Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. Am J Hematol. 2019 Dec.94(12):E314-E317. Pubmedid: [31444809](https://www.ncbi.nlm.nih.gov/pubmed/31444809). 
    * Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leuk Lymphoma. 2019 Dec.60(13):3161-3171. Pubmedid: [31111762](https://www.ncbi.nlm.nih.gov/pubmed/31111762). Pmcid: PMC7757428. 
    * Komrokji RS. Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS. Curr Hematol Malig Rep. 2019 Aug.14(4):346-351. Pubmedid: [31203517](https://www.ncbi.nlm.nih.gov/pubmed/31203517). 
    * Mora B, Rumi E, Guglielmelli P, Barraco D, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Pietra D, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Giorgino T, Passamonti F. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019 Aug.8(9):4089-4092. Pubmedid: [31173472](https://www.ncbi.nlm.nih.gov/pubmed/31173472). Pmcid: PMC6675726. 
    * Komrokji RS, Al Ali NH, Padron E, Cogle C, Tinsley S, Sallman D, Lancet JE, List AF. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial. Clin Lymphoma Myeloma Leuk. 2019 Apr.19(4):251-254. Pubmedid: [30852241](https://www.ncbi.nlm.nih.gov/pubmed/30852241). 
    * Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Merli M, Pietra D, Barbui T, Rotunno G, Cazzola M, Giorgino T, Vannucchi AM, Passamonti F. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018 Sep.8(10):89. Pubmedid: [30291232](https://www.ncbi.nlm.nih.gov/pubmed/30291232). Pmcid: PMC6173714. 
    * Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematol. 2018 Sep.5(9):e393-e402. Pubmedid: [30072146](https://www.ncbi.nlm.nih.gov/pubmed/30072146). Pmcid: PMC6505461. 
    * Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Merli M, Pietra D, Casalone R, Barbui T, Rotunno G, Cazzola M, Vannucchi AM, Passamonti F. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018 Sep.103(9):e392-e394. Pubmedid: [29622658](https://www.ncbi.nlm.nih.gov/pubmed/29622658). Pmcid: PMC6119135. 
    * Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am J Hematol. 2018 Oct.93(10):1245-1253. Pubmedid: [30051599](https://www.ncbi.nlm.nih.gov/pubmed/30051599). Pmcid: PMC6750209. 
    * Vela CM, Van den Bergh M, Gillis NK, Ball M, Hussaini MO, Walko CM, Hicks JK, Perez L, Padron E, Komrokji RS. Somatic Sequencing Identifies Trametinib-Responsive Myelodysplastic Syndrome and Finds Acquired Clonal Hematopoiesis of Indeterminate Potential. JCO Precis Oncol. 2018 Nov.2. Pubmedid: [35135101](https://www.ncbi.nlm.nih.gov/pubmed/35135101). Pmcid: PMC9797240. 
    * Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 Nov.132(19):2100-2103. Pubmedid: [30242087](https://www.ncbi.nlm.nih.gov/pubmed/30242087). Pmcid: PMC6236463. 
    * Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leuk Lymphoma. 2018 Nov.59(11):2723-2726. Pubmedid: [29667455](https://www.ncbi.nlm.nih.gov/pubmed/29667455). 
    * Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 2018 May.131(21):2402-2405. Pubmedid: [29661788](https://www.ncbi.nlm.nih.gov/pubmed/29661788). Pmcid: PMC5969383. 
    * Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar.97(3):435-441. Pubmedid: [29189896](https://www.ncbi.nlm.nih.gov/pubmed/29189896). 
    * Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J. Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience. Cancer Genomics Proteomics. 2018 Mar.15(2):121-126. Pubmedid: [29496691](https://www.ncbi.nlm.nih.gov/pubmed/29496691). Pmcid: PMC5892606. 
    * Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 Jul.2(14):1765-1772. Pubmedid: [30037803](https://www.ncbi.nlm.nih.gov/pubmed/30037803). Pmcid: PMC6058241. 
    * Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver N. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 Jul.59(7):1672-1676. Pubmedid: [29119847](https://www.ncbi.nlm.nih.gov/pubmed/29119847). 
    * Shammo JM, Komrokji RS. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy. Expert Rev Hematol. 2018 Jul.11(7):577-586. Pubmedid: [29902097](https://www.ncbi.nlm.nih.gov/pubmed/29902097). 
    * Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018 Feb.5(2):e63-e72. Pubmedid: [29331635](https://www.ncbi.nlm.nih.gov/pubmed/29331635). 
    * Komrokji R, Swern AS, Grinblatt D, Lyons RM, Tobiasson M, Silverman LR, Sayar H, Vij R, Fliss A, Tu N, Sugrue MM. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. Oncologist. 2018 Feb.23(2):159-170. Pubmedid: [29118268](https://www.ncbi.nlm.nih.gov/pubmed/29118268). Pmcid: PMC5813747. 
    * Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Ann Hematol. 2018 Feb.97(2):247-254. Pubmedid: [29167940](https://www.ncbi.nlm.nih.gov/pubmed/29167940). 
    * Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E. Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia. Leukemia. 2018 Feb.32(2):532-538. Pubmedid: [28694526](https://www.ncbi.nlm.nih.gov/pubmed/28694526). Pmcid: PMC7771351. 
    * Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA. Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer. 2018 Dec.124(24):4601-4609. Pubmedid: [30289970](https://www.ncbi.nlm.nih.gov/pubmed/30289970). 
    * Stahl M, DeVeaux M, Fernández PM, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biol Blood Marrow Tr. 2018 Aug.24(8):1754-1758. Pubmedid: [29649620](https://www.ncbi.nlm.nih.gov/pubmed/29649620). 
    * Ball B, Komrokji RS, Adès L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, Platzbecker U, Gore SD, Fenaux P, Prebet T. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv. 2018 Aug.2(16):2063-2071. Pubmedid: [30120104](https://www.ncbi.nlm.nih.gov/pubmed/30120104). Pmcid: PMC6113613. 
    * Migdady Y, Barnard J, Al Ali N, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Sekeres MA, Komrokji RS. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. Clin Lymphoma Myeloma Leuk. 2018 Aug.18(8):528-532. Pubmedid: [29937400](https://www.ncbi.nlm.nih.gov/pubmed/29937400). 
    * El Fakih R, Komrokji R, Shaheen M, Almohareb F, Rasheed W, Hassanein M. Azacitidine Use for Myeloid Neoplasms. Clin Lymphoma Myeloma Leuk. 2018 Apr.18(4):e147-e155. Pubmedid: [29478947](https://www.ncbi.nlm.nih.gov/pubmed/29478947). 
    * Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 Apr.2(8):923-932. Pubmedid: [29685952](https://www.ncbi.nlm.nih.gov/pubmed/29685952). Pmcid: PMC5916007. 
    * Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Cavalloni C, Barraco D, Pietra D, Barbui T, Rotunno G, Vannucchi AM, Passamonti F. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leuk Res. 2018 06.69:100-102. Pubmedid: [29734070](https://www.ncbi.nlm.nih.gov/pubmed/29734070). 
    * Zeidan AM, Pullarkat VA, Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome. Crit Rev Oncol Hematol. 2017 Sep.117:57-66. Pubmedid: [28807236](https://www.ncbi.nlm.nih.gov/pubmed/28807236). 
    * Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Sep.130(13):1514-1522. Pubmedid: [28774880](https://www.ncbi.nlm.nih.gov/pubmed/28774880). Pmcid: PMC5620419. 
    * Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer. 2017 Oct.123(19):3662-3672. Pubmedid: [28759108](https://www.ncbi.nlm.nih.gov/pubmed/28759108). 
    * Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J, Komrokji R, Djeu J, List A, Wei S. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017 Oct.31(10):2172-2180. Pubmedid: [28096534](https://www.ncbi.nlm.nih.gov/pubmed/28096534). Pmcid: PMC5552472. 
    * Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, Gore SD, Komrokji R. Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget. 2017 Oct.8(47):81926-81935. Pubmedid: [29137233](https://www.ncbi.nlm.nih.gov/pubmed/29137233). Pmcid: PMC5669859. 
    * Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Nov.17(11):753-758. Pubmedid: [28687222](https://www.ncbi.nlm.nih.gov/pubmed/28687222). Pmcid: PMC5675815. 
    * Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017 May.123(6):994-1002. Pubmedid: [28094841](https://www.ncbi.nlm.nih.gov/pubmed/28094841). Pmcid: PMC5432122. 
    * Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. J Clin Oncol. 2017 May.35(14):1591-1597. Pubmedid: [28350519](https://www.ncbi.nlm.nih.gov/pubmed/28350519). 
    * Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar.92(3):232-237. Pubmedid: [28006850](https://www.ncbi.nlm.nih.gov/pubmed/28006850). 
    * Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. 2017 Mar.129(13):1881-1883. Pubmedid: [28159734](https://www.ncbi.nlm.nih.gov/pubmed/28159734). 
    * Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017 Mar.58(3):560-568. Pubmedid: [27424609](https://www.ncbi.nlm.nih.gov/pubmed/27424609). Pmcid: PMC7771364. 
    * Prebet T, Toma A, Cluzeau T, Sekeres MA, Vey N, Park S, Al Ali N, Sugrue MM, Komrokji R, Fenaux P, Gore SD. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget. 2017 Jun.8(23):37866-37874. Pubmedid: [28184031](https://www.ncbi.nlm.nih.gov/pubmed/28184031). Pmcid: PMC5514957. 
    * Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017 Jun.31(6):1391-1397. Pubmedid: [28111463](https://www.ncbi.nlm.nih.gov/pubmed/28111463). 
    * DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Leuk Lymphoma. 2017 Jun.58(6):1325-1331. Pubmedid: [27774847](https://www.ncbi.nlm.nih.gov/pubmed/27774847). Pmcid: PMC5394924. 
    * Nassereddine S, Nishihori T, Padron E, Mahfouz R, Bazarbachi A, Komrokji RS, Kharfan-Dabaja MA. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2017 Jan.17(1):7-13. Pubmedid: [27771290](https://www.ncbi.nlm.nih.gov/pubmed/27771290). 
    * Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan.18(1):112-121. Pubmedid: [27927582](https://www.ncbi.nlm.nih.gov/pubmed/27927582). Pmcid: PMC7771361. 
    * Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2017 Jan.15(1):60-87. Pubmedid: [28040720](https://www.ncbi.nlm.nih.gov/pubmed/28040720). 
    * Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion. 2017 Feb.57(2):289-295. Pubmedid: [27878822](https://www.ncbi.nlm.nih.gov/pubmed/27878822). Pmcid: PMC5309168. 
    * Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):e45-e53. Pubmedid: [28869184](https://www.ncbi.nlm.nih.gov/pubmed/28869184). 
    * Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leuk Res. 2017 Dec.63:72-77. Pubmedid: [29112938](https://www.ncbi.nlm.nih.gov/pubmed/29112938). 
    * Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec.17(12):902-907. Pubmedid: [29030092](https://www.ncbi.nlm.nih.gov/pubmed/29030092). 
    * Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer J. 2017 Dec.7(12):644. Pubmedid: [29238044](https://www.ncbi.nlm.nih.gov/pubmed/29238044). Pmcid: PMC5802598. 
    * Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I. Clin Lymphoma Myeloma Leuk. 2017 Aug.17(8):479-487. Pubmedid: [28606598](https://www.ncbi.nlm.nih.gov/pubmed/28606598). Pmcid: PMC8148882. 
    * Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2017 Apr.17(4):211-214. Pubmedid: [28185797](https://www.ncbi.nlm.nih.gov/pubmed/28185797). 
    * Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J. ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS. Blood Cancer J. 2017 11.7(12):633. Pubmedid: [29176559](https://www.ncbi.nlm.nih.gov/pubmed/29176559). Pmcid: PMC5802523. 
    * Zeidan AM, Sekeres MA, Barnard J, Steensma DP, Komrokji R. Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse?. Leukemia. 2017 11.31(11):2539-2541. Pubmedid: [28757618](https://www.ncbi.nlm.nih.gov/pubmed/28757618). 
    * Komrokji RS. Use of eltrombopag for treatment of myelodysplastic syndromes. Lancet Haematol. 2017 03.4(3):e99-e100. Pubmedid: [28257755](https://www.ncbi.nlm.nih.gov/pubmed/28257755). 
    * Sallman DA, Komrokji R, List A, Padron E. Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'. Leukemia. 2017 03.31(3):767-768. Pubmedid: [27740632](https://www.ncbi.nlm.nih.gov/pubmed/27740632). 
    * Zeidan AM, Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opin Emerg Drugs. 2016 Sep.21(3):283-300. Pubmedid: [27486848](https://www.ncbi.nlm.nih.gov/pubmed/27486848). 
    * Mesa RA, Komrokji RS, Verstovsek S. Ruxolitinib dose management as a key to long-term treatment success. Int J Hematol. 2016 Oct.104(4):420-429. Pubmedid: [27567907](https://www.ncbi.nlm.nih.gov/pubmed/27567907). 
    * Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. 2016 Nov.101(11):e457-e460. Pubmedid: [27418649](https://www.ncbi.nlm.nih.gov/pubmed/27418649). Pmcid: PMC5394875. 
    * Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016 May.91(5):E280-E283. Pubmedid: [26875020](https://www.ncbi.nlm.nih.gov/pubmed/26875020). 
    * Suleiman Y, Dalia S, Liu JJ, Bowers JW, Padron E, Lancet JE, Fulp W, Moscinski LC, Komrokji RS, Zuckerman KS, Zhang L. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia. Leuk Res. 2016 Mar.42:52-58. Pubmedid: [26894965](https://www.ncbi.nlm.nih.gov/pubmed/26894965). 
    * Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016 Mar.30(3):649-657. Pubmedid: [26464171](https://www.ncbi.nlm.nih.gov/pubmed/26464171). Pmcid: PMC4775363. 
    * Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016 Mar.30(3):666-673. Pubmedid: [26514544](https://www.ncbi.nlm.nih.gov/pubmed/26514544). Pmcid: PMC7864381. 
    * Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Res. 2016 Jun.76(12):3531-3540. Pubmedid: [27197154](https://www.ncbi.nlm.nih.gov/pubmed/27197154). Pmcid: PMC4911265. 
    * Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med. 2016 Jul.5(7):1694-1701. Pubmedid: [27098006](https://www.ncbi.nlm.nih.gov/pubmed/27098006). Pmcid: PMC4944897. 
    * Komrokji RS, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Ann Oncol. 2016 Jan.27(1):62-68. Pubmedid: [26504152](https://www.ncbi.nlm.nih.gov/pubmed/26504152). Pmcid: PMC4684154. 
    * Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb.41:43-47. Pubmedid: [26777537](https://www.ncbi.nlm.nih.gov/pubmed/26777537). Pmcid: PMC4986515. 
    * Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec.128(25):2960-2975. Pubmedid: [27737891](https://www.ncbi.nlm.nih.gov/pubmed/27737891). Pmcid: PMC5179338. 
    * McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016 Aug.101(8):e320-e323. Pubmedid: [27081179](https://www.ncbi.nlm.nih.gov/pubmed/27081179). Pmcid: PMC4967580. 
    * Komrokji RS. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S39-S43. Pubmedid: [27521322](https://www.ncbi.nlm.nih.gov/pubmed/27521322). 
    * Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S64-S66. Pubmedid: [27521328](https://www.ncbi.nlm.nih.gov/pubmed/27521328). 
    * Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S53-S56. Pubmedid: [27521325](https://www.ncbi.nlm.nih.gov/pubmed/27521325). 
    * Roe C, Komrokji R, Zhang L, Price S, Sokol L. Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S191-S194. Pubmedid: [27521318](https://www.ncbi.nlm.nih.gov/pubmed/27521318). 
    * Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S44-S48. Pubmedid: [27521323](https://www.ncbi.nlm.nih.gov/pubmed/27521323). 
    * Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug.47:78-83. Pubmedid: [27285853](https://www.ncbi.nlm.nih.gov/pubmed/27285853). 
    * Verstovsek S, Komrokji RS. A comprehensive review of pacritinib in myelofibrosis. Future Oncol. 2016 Aug.11(20):2819-2830. Pubmedid: [26367195](https://www.ncbi.nlm.nih.gov/pubmed/26367195). Pmcid: PMC4918816. 
    * Singer JW, Al-Fayoumi S, Ma H, Komrokji RS, Mesa R, Verstovsek S. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J Exp Pharmacol. 2016 Aug.8:11-19. Pubmedid: [27574472](https://www.ncbi.nlm.nih.gov/pubmed/27574472). Pmcid: PMC4993559. 
    * Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer. 2016 Aug.16:652. Pubmedid: [27538433](https://www.ncbi.nlm.nih.gov/pubmed/27538433). Pmcid: PMC4991094. 
    * Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016 Aug.22(15):3746-3754. Pubmedid: [26858309](https://www.ncbi.nlm.nih.gov/pubmed/26858309). Pmcid: PMC5278764. 
    * Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther. 2016 Aug.9:4937-4957. Pubmedid: [27570458](https://www.ncbi.nlm.nih.gov/pubmed/27570458). Pmcid: PMC4986686. 
    * Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Al Ali N, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 06.101(6):e224-e227. Pubmedid: [26992944](https://www.ncbi.nlm.nih.gov/pubmed/26992944). Pmcid: PMC5013943. 
    * Komrokji RS. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2016.35:e345-e352. Pubmedid: [27249741](https://www.ncbi.nlm.nih.gov/pubmed/27249741). 
    * Griffin PT, Komrokji RS, DeCastro CM, Rizzieri DA, Melchert M, List AF, Lancet JE. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. Am J Hematol. 2015 Sep.90(9):796-799. Pubmedid: [26089240](https://www.ncbi.nlm.nih.gov/pubmed/26089240). 
    * Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 2015 Sep.100(9):1117-1130. Pubmedid: [26341525](https://www.ncbi.nlm.nih.gov/pubmed/26341525). Pmcid: PMC4800699. 
    * Nishihori T, El-Asmar J, Shah B, Hussaini M, Komrokji R, List A, Anasetti C, Kharfan-Dabaja MA. Donor-derived constitutional chromosomal abnormalities after allogeneic hematopoietic cell transplantation: a single-center experience and a review of the literature. Bone Marrow Transplant. 2015 Oct.50(10):1388-1392. Pubmedid: [26191951](https://www.ncbi.nlm.nih.gov/pubmed/26191951). 
    * Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. Am J Hematol. 2015 Nov.90(11):1036-1040. Pubmedid: [26284571](https://www.ncbi.nlm.nih.gov/pubmed/26284571). 
    * Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clin Lymphoma Myeloma Leuk. 2015 Nov.15(11):705-710. Pubmedid: [26440749](https://www.ncbi.nlm.nih.gov/pubmed/26440749). 
    * Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. J Clin Oncol. 2015 Nov.33(33):3953-3960. Pubmedid: [26324368](https://www.ncbi.nlm.nih.gov/pubmed/26324368). Pmcid: PMC4979103. 
    * Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar.121(6):876-882. Pubmedid: [25410759](https://www.ncbi.nlm.nih.gov/pubmed/25410759). Pmcid: PMC4378905. 
    * Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C. Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Ne. 2015 Mar.13(3):261-272. Pubmedid: [25736003](https://www.ncbi.nlm.nih.gov/pubmed/25736003). Pmcid: PMC4696005. 
    * Zeidan AM, Gore SD, Padron E, Komrokji RS. Current state of prognostication and risk stratification in myelodysplastic syndromes. Curr Opin Hematol. 2015 Mar.22(2):146-154. Pubmedid: [25575032](https://www.ncbi.nlm.nih.gov/pubmed/25575032). 
    * Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 2015 Mar.125(12):1857-1865. Pubmedid: [25624319](https://www.ncbi.nlm.nih.gov/pubmed/25624319). Pmcid: PMC4915792. 
    * Garcia-Manero G, Khoury HJ, Jabbour E, Lancet JE, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, List AF, Kantarjian H, Komrokji RS. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015 Mar.21(5):985-994. Pubmedid: [25480830](https://www.ncbi.nlm.nih.gov/pubmed/25480830). Pmcid: PMC4348327. 
    * Komrokji R, Ramadan H, Al Ali N, Corrales-Yepez M, Zhang L, Padron E, Lancet J, List A. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S60-S63. Pubmedid: [26297280](https://www.ncbi.nlm.nih.gov/pubmed/26297280). 
    * Chavez JC, Dalia S, Sandoval-Sus J, Kharfan-Dabaja MA, Al-Ali N, Komrokji R, Padron E, Corrales-Yepez G, Rock-Klotz J, Pinilla-Ibarz J. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S14-S18. Pubmedid: [26297266](https://www.ncbi.nlm.nih.gov/pubmed/26297266). 
    * Roe C, Bennett J, Zhang L, Chavez J, Shah B, Sokol L, Komrokji R. Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten?. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S147-S150. Pubmedid: [26297268](https://www.ncbi.nlm.nih.gov/pubmed/26297268). 
    * Komrokji RS. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S56-S59. Pubmedid: [26297279](https://www.ncbi.nlm.nih.gov/pubmed/26297279). 
    * Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Impact of tobacco usage on disease outcome in myelodysplastic syndromes. Leuk Res. 2015 Jul.39(7):673-678. Pubmedid: [25934048](https://www.ncbi.nlm.nih.gov/pubmed/25934048). Pmcid: PMC5992898. 
    * Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, Sekeres MA, List AF, Onida F, Komrokji RS, Tefferi A, Solary E. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015 Jul.5:e333. Pubmedid: [26230957](https://www.ncbi.nlm.nih.gov/pubmed/26230957). Pmcid: PMC4526779. 
    * Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015 Jul.90(7):602-607. Pubmedid: [25802083](https://www.ncbi.nlm.nih.gov/pubmed/25802083). Pmcid: PMC4617516. 
    * Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, Ketterling RP, Komrokji R, Tefferi A, Solary E. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015 Jan.5:e270. Pubmedid: [25555161](https://www.ncbi.nlm.nih.gov/pubmed/25555161). Pmcid: PMC5404217. 
    * Nishihori T, Komrokji R, Shain K, Anasetti C. Allogeneic hematopoietic cell transplantation for concurrent multiple myeloma and myelodysplastic syndrome. Bone Marrow Transplant. 2015 Feb.50(2):296-297. Pubmedid: [25330222](https://www.ncbi.nlm.nih.gov/pubmed/25330222). 
    * Verstovsek S, Komrokji RS. Novel and emerging therapies for the treatment of polycythemia vera. Expert Rev Hematol. 2015 Feb.8(1):101-113. Pubmedid: [25353086](https://www.ncbi.nlm.nih.gov/pubmed/25353086). Pmcid: PMC4934659. 
    * Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?. Am J Hematol. 2015 Aug. Pubmedid: [26260295](https://www.ncbi.nlm.nih.gov/pubmed/26260295). Pmcid: PMC4751065. 
    * Grinblatt DL, Sekeres MA, Komrokji RS, Swern AS, Sullivan KA, Narang M. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Leuk Lymphoma. 2015 Apr.56(4):887-895. Pubmedid: [24956145](https://www.ncbi.nlm.nih.gov/pubmed/24956145). 
    * Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Ne. 2015 Apr.13(4):424-434. Pubmedid: [25870379](https://www.ncbi.nlm.nih.gov/pubmed/25870379). Pmcid: PMC8161684. 
    * Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematol. 2015 Apr.133(2):249-256. Pubmedid: [25413011](https://www.ncbi.nlm.nih.gov/pubmed/25413011). 
    * Komrokji RS, Seymour JF, Roberts AW, Wadleigh M, To LB, Scherber R, Turba E, Dorr A, Zhu J, Wang L, Granston T, Campbell MS, Mesa RA. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr.125(17):2649-2655. Pubmedid: [25762180](https://www.ncbi.nlm.nih.gov/pubmed/25762180). Pmcid: PMC4490373. 
    * Duong VH, Komrokji RS, List AF. Update on the pharmacotherapy for myelodysplastic syndromes. Expert Opin Pharmacother. 2014 Sep.15(13):1811-1825. Pubmedid: [25080144](https://www.ncbi.nlm.nih.gov/pubmed/25080144). 
    * Garcia-Manero G, Gartenberg G, Steensma DP, Schipperus MR, Breems DA, de Paz R, Valcárcel D, Kranenburg B, Reddy M, Komrokji RS. A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome. Am J Hematol. 2014 Sep.89(9):E156-E162. Pubmedid: [24888488](https://www.ncbi.nlm.nih.gov/pubmed/24888488). 
    * Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May.123(21):3239-3246. Pubmedid: [24687088](https://www.ncbi.nlm.nih.gov/pubmed/24687088). Pmcid: PMC4624448. 
    * Padron E, Komrokji R, List AF. The clinical management of chronic myelomonocytic leukemia. Clin Adv Hematol Oncol. 2014 Mar.12(3):172-178. Pubmedid: [24927265](https://www.ncbi.nlm.nih.gov/pubmed/24927265). 
    * Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol. 2014 Mar.21(2):123-130. Pubmedid: [24335709](https://www.ncbi.nlm.nih.gov/pubmed/24335709). Pmcid: PMC4124617. 
    * Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biol Blood Marrow Tr. 2014 Jun.20(6):776-780. Pubmedid: [24534108](https://www.ncbi.nlm.nih.gov/pubmed/24534108). 
    * Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, Dennison B, Sekeres MA. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014 Jun.120(11):1670-1676. Pubmedid: [24577838](https://www.ncbi.nlm.nih.gov/pubmed/24577838). 
    * Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 2014 Jun.123(23):3675-3677. Pubmedid: [24904105](https://www.ncbi.nlm.nih.gov/pubmed/24904105). Pmcid: PMC4047502. 
    * Duong VH, Komrokji RS. The role of pacritinib in the management of myelofibrosis. Expert Rev Hematol. 2014 Jun.7(3):325-332. Pubmedid: [24746271](https://www.ncbi.nlm.nih.gov/pubmed/24746271). 
    * Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014 Jul.99(7):1176-1183. Pubmedid: [24488560](https://www.ncbi.nlm.nih.gov/pubmed/24488560). Pmcid: PMC4077078. 
    * Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. Int J Hematol. 2014 Dec.100(6):567-574. Pubmedid: [25281405](https://www.ncbi.nlm.nih.gov/pubmed/25281405). 
    * Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014 Aug.89(8):809-812. Pubmedid: [24764152](https://www.ncbi.nlm.nih.gov/pubmed/24764152). Pmcid: PMC4561860. 
    * Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leuk Res. 2014 Apr.38(4):443-446. Pubmedid: [24439565](https://www.ncbi.nlm.nih.gov/pubmed/24439565). 
    * Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep.13 Suppl 2:S295-S299. Pubmedid: [24290214](https://www.ncbi.nlm.nih.gov/pubmed/24290214). 
    * Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013 Oct.110(40):16127-16132. Pubmedid: [24043769](https://www.ncbi.nlm.nih.gov/pubmed/24043769). Pmcid: PMC3791697. 
    * Duong VH, Padron E, List AF, Komrokji RS. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?. Expert Rev Hematol. 2013 Oct.6(5):485-487. Pubmedid: [24083503](https://www.ncbi.nlm.nih.gov/pubmed/24083503). 
    * Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, Lancet JE, Fernandez HF, Djulbegovic B, Kumar A. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Brit J Haematol. 2013 Nov.163(3):315-325. Pubmedid: [24033280](https://www.ncbi.nlm.nih.gov/pubmed/24033280). 
    * Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leuk Res. 2013 May.37(5):510-515. Pubmedid: [23332452](https://www.ncbi.nlm.nih.gov/pubmed/23332452). 
    * Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res. 2013 Mar.37(3):300-304. Pubmedid: [23273539](https://www.ncbi.nlm.nih.gov/pubmed/23273539). 
    * Bejar R, Tiu RV, Sekeres MA, Komrokji RS. Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges. Am Soc Clin Oncol Educ Book. 2013 Jun. Pubmedid: [23714517](https://www.ncbi.nlm.nih.gov/pubmed/23714517). 
    * Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013 Jun.121(25):5068-5077. Pubmedid: [23632888](https://www.ncbi.nlm.nih.gov/pubmed/23632888). Pmcid: PMC4347259. 
    * Zeidan AM, Gore SD, Komrokji RS. Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?. Expert Rev Hematol. 2013 Jun.6(3):251-254. Pubmedid: [23782079](https://www.ncbi.nlm.nih.gov/pubmed/23782079). 
    * Adès L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P, Komrokji RS. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013 Jun.37(6):609-613. Pubmedid: [23415110](https://www.ncbi.nlm.nih.gov/pubmed/23415110). 
    * Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M. Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Ne. 2013 Jul.11(7):838-874. Pubmedid: [23847220](https://www.ncbi.nlm.nih.gov/pubmed/23847220). Pmcid: PMC4000017. 
    * Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma. 2013 Jul.54(7):1373-1379. Pubmedid: [23278639](https://www.ncbi.nlm.nih.gov/pubmed/23278639). 
    * Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A, Pardanani A, Ali NA, Komrokji RS, Komroji RS, Tefferi A. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013 Jul.27(7):1504-1510. Pubmedid: [23531518](https://www.ncbi.nlm.nih.gov/pubmed/23531518). 
    * Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol. 2013 Jul.88(7):566-570. Pubmedid: [23605934](https://www.ncbi.nlm.nih.gov/pubmed/23605934). Pmcid: PMC4685468. 
    * Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb.32(9):1110-1120. Pubmedid: [22525275](https://www.ncbi.nlm.nih.gov/pubmed/22525275). Pmcid: PMC3751397. 
    * Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. Ruxolitinib for myelofibrosis--an update of its clinical effects. Clin Lymphoma Myeloma Leuk. 2013 Dec.13(6):638-645. Pubmedid: [24238036](https://www.ncbi.nlm.nih.gov/pubmed/24238036). Pmcid: PMC5556922. 
    * Zeidan AM, Komrokji RS. There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep. 2013 Dec.8(4):351-360. Pubmedid: [23979829](https://www.ncbi.nlm.nih.gov/pubmed/23979829). Pmcid: PMC4133773. 
    * Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clin Lymphoma Myeloma Leuk. 2013 Dec.13(6):711-715. Pubmedid: [24054159](https://www.ncbi.nlm.nih.gov/pubmed/24054159). 
    * Komrokji RS, Padron E, Ebert BL, List AF. Deletion 5q MDS: molecular and therapeutic implications. Best Pract Res Clin Haematol. 2013 Dec.26(4):365-375. Pubmedid: [24507813](https://www.ncbi.nlm.nih.gov/pubmed/24507813). 
    * Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, Wilhelm F, List AF. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Brit J Haematol. 2013 Aug.162(4):517-524. Pubmedid: [23789936](https://www.ncbi.nlm.nih.gov/pubmed/23789936). Pmcid: PMC4685467. 
    * Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr.21(4):1097-1103. Pubmedid: [23179489](https://www.ncbi.nlm.nih.gov/pubmed/23179489). 
    * Zeidan AM, Smith BD, Komrokji RS, Gore SD. Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am J Med. 2013 Apr.126(4):e25. Pubmedid: [23507216](https://www.ncbi.nlm.nih.gov/pubmed/23507216). Pmcid: PMC3768129. 
    * Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 2013 Apr.27(4):897-906. Pubmedid: [23072779](https://www.ncbi.nlm.nih.gov/pubmed/23072779). Pmcid: PMC4346223. 
    * Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012 Sep.189(6):3198-3208. Pubmedid: [22875800](https://www.ncbi.nlm.nih.gov/pubmed/22875800). Pmcid: PMC3436939. 
    * Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control. 2012 Oct.19(4 Suppl):4-15. Pubmedid: [23042420](https://www.ncbi.nlm.nih.gov/pubmed/23042420). 
    * Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012 Oct.120(17):3419-3424. Pubmedid: [22936658](https://www.ncbi.nlm.nih.gov/pubmed/22936658). 
    * Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol. 2012 Nov.87(11):1006-1009. Pubmedid: [23090887](https://www.ncbi.nlm.nih.gov/pubmed/23090887). 
    * Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 2012 May.118(10):2659-2664. Pubmedid: [21956402](https://www.ncbi.nlm.nih.gov/pubmed/21956402). 
    * Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012 Jan.36(1):72-80. Pubmedid: [21782240](https://www.ncbi.nlm.nih.gov/pubmed/21782240). 
    * Carballido E, Veliz M, Komrokji R, Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control. 2012 Jan.19(1):54-67. Pubmedid: [22143062](https://www.ncbi.nlm.nih.gov/pubmed/22143062). 
    * Komrokji R, Verstovsek S. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Rev Hematol. 2012 Dec.5(6):631-641. Pubmedid: [23216593](https://www.ncbi.nlm.nih.gov/pubmed/23216593). 
    * Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 2012 Dec.120(25):4945-4951. Pubmedid: [22915641](https://www.ncbi.nlm.nih.gov/pubmed/22915641). Pmcid: PMC3525020. 
    * Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012 Apr.118(8):2138-2147. Pubmedid: [21887679](https://www.ncbi.nlm.nih.gov/pubmed/21887679). 
    * Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Ther Adv Hematol. 2012 Apr.3(2):105-116. Pubmedid: [23556117](https://www.ncbi.nlm.nih.gov/pubmed/23556117). Pmcid: PMC3573434. 
    * Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes. Curr Pharm Des. 2012.18(22):3198-3203. Pubmedid: [22571699](https://www.ncbi.nlm.nih.gov/pubmed/22571699). 
    * Komrokji RS, List AF. Role of lenalidomide in the treatment of myelodysplastic syndromes. Semin Oncol. 2011 Oct.38(5):648-657. Pubmedid: [21943671](https://www.ncbi.nlm.nih.gov/pubmed/21943671). 
    * Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R. Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. J Clin Oncol. 2011 May.29(15):e434-e436. Pubmedid: [21149648](https://www.ncbi.nlm.nih.gov/pubmed/21149648). 
    * Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancetf J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Tr. 2011 Mar.17(3):384-393. Pubmedid: [20655389](https://www.ncbi.nlm.nih.gov/pubmed/20655389). 
    * Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res. 2011 Mar.35(3):301-304. Pubmedid: [21109304](https://www.ncbi.nlm.nih.gov/pubmed/21109304). 
    * Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun.11(3):257-260. Pubmedid: [21658652](https://www.ncbi.nlm.nih.gov/pubmed/21658652). 
    * Nishihori T, Fernandez HF, Coppola D, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Kharfan-Dabaja MA. Hepatobiliary manifestations of acute myeloid leukemia. Leuk Res. 2011 Jun.35(6):e81-e83. Pubmedid: [21232795](https://www.ncbi.nlm.nih.gov/pubmed/21232795). 
    * Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr Hematol Malig Rep. 2011 Jun.6(2):145-153. Pubmedid: [21442178](https://www.ncbi.nlm.nih.gov/pubmed/21442178). 
    * Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Ne. 2011 Jan.9(1):30-56. Pubmedid: [21233243](https://www.ncbi.nlm.nih.gov/pubmed/21233243). Pmcid: PMC3768131. 
    * Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Rev Hematol. 2011 Feb.4(1):61-69. Pubmedid: [21322779](https://www.ncbi.nlm.nih.gov/pubmed/21322779). 
    * Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. CURR TREAT OPTION ON. 2011 Dec.12(4):354-368. Pubmedid: [21964863](https://www.ncbi.nlm.nih.gov/pubmed/21964863). 
    * Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011 Aug.52(8):1528-1536. Pubmedid: [21635204](https://www.ncbi.nlm.nih.gov/pubmed/21635204). Pmcid: PMC4350661. 
    * Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 2011 Apr.117(7):1463-1469. Pubmedid: [21425147](https://www.ncbi.nlm.nih.gov/pubmed/21425147). Pmcid: PMC4545502. 
    * Ortega J, Komrokji R, List AF. The hematopoietic growth factors in the myelodysplastic syndromes. Cancer Treat Res. 2011.157:363-382. Pubmedid: [21052966](https://www.ncbi.nlm.nih.gov/pubmed/21052966). 
    * Nishihori T, Perkins J, Kim J, Field T, Pidala J, Roman-Diaz J, Komrokji RS, Fernandez HF, Anasetti C, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution. Am J Hematol. 2010 Nov.85(11):904-907. Pubmedid: [20890908](https://www.ncbi.nlm.nih.gov/pubmed/20890908). 
    * Komrokji RS, Lancet JE, List AF. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?. Curr Hematol Malig Rep. 2010 Jan.5(1):9-14. Pubmedid: [20425391](https://www.ncbi.nlm.nih.gov/pubmed/20425391). 
    * Komrokji RS, Matacia-Murphy GM, Al Ali NH, Beg MS, Safa MM, Rollison DE, List AF. Outcome of patients with myelodysplastic syndromes in the Veterans Administration population. Leuk Res. 2010 Jan.34(1):59-62. Pubmedid: [19368972](https://www.ncbi.nlm.nih.gov/pubmed/19368972). 
    * Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 2010 Feb.95(2):340-342. Pubmedid: [19850902](https://www.ncbi.nlm.nih.gov/pubmed/19850902). Pmcid: PMC2817042. 
    * Khan AM, Komrokji RS, Haddad RY. Myelodysplastic syndromes: what a primary care physician needs to know. Dis Mon. 2010 Aug.56(8):468-478. Pubmedid: [20800756](https://www.ncbi.nlm.nih.gov/pubmed/20800756). 
    * Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am. 2010 Apr.24(2):443-457. Pubmedid: [20359636](https://www.ncbi.nlm.nih.gov/pubmed/20359636). 
    * Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010 Apr.24(2):377-388. Pubmedid: [20359632](https://www.ncbi.nlm.nih.gov/pubmed/20359632). 
    * Ahmed F, Osman N, Lucas F, Neff G, Smolarek T, Bennett JM, Komrokji RS. Therapy related CMML: a case report and review of the literature. Int J Hematol. 2009 Jun.89(5):699-703. Pubmedid: [19430863](https://www.ncbi.nlm.nih.gov/pubmed/19430863). 
    * Beg M, Komrokji R, Ahmed K, Safa M. Oxaliplatin-induced immune mediated thrombocytopenia. Cancer Chemother Pharmacol. 2008 Oct.62(5):925-927. Pubmedid: [18204841](https://www.ncbi.nlm.nih.gov/pubmed/18204841). 
    * Walker AR, Komrokji RJ, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec.32(12):1830-1836. Pubmedid: [18571721](https://www.ncbi.nlm.nih.gov/pubmed/18571721). 
    * Komrokji R, Bennett J. Evolving classifications of the myelodysplastic syndromes. Curr Opin Hematol. 2007 Mar.14(2):98-105. Pubmedid: [17255786](https://www.ncbi.nlm.nih.gov/pubmed/17255786). 
    * Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer. 2007 Apr.109(8):1471-1477. Pubmedid: [17342768](https://www.ncbi.nlm.nih.gov/pubmed/17342768). 
    * Komrokji R. Myelodysplastic syndromes: a view from where the sun rises and where the sun sets. Leuk Res. 2006 Sep.30(9):1067-1068. Pubmedid: [16723153](https://www.ncbi.nlm.nih.gov/pubmed/16723153). 
    * Nahleh Z, Komrokji R, Jazieh A, Benedetti J, Sparks D. Cancer research training: the Southwest Oncology Group young investigator training program (YITP). J Cancer Educ. 2006 Oct.21(2):77-79. Pubmedid: [17020517](https://www.ncbi.nlm.nih.gov/pubmed/17020517). 
    * Komrokji RS, Bennett JM. Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification. Curr Hematol Malig Rep. 2006 Mar.1(1):9-15. Pubmedid: [20425325](https://www.ncbi.nlm.nih.gov/pubmed/20425325). 
    * Komrokji R, Uppal N, Khorana A, Lyman G, Kaplan K, Fisher R, Francis C. Venous thromboembolism in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006 Jun.47(6):1029-1033. Pubmedid: [16840193](https://www.ncbi.nlm.nih.gov/pubmed/16840193). 
    * Komrokji R, Bennett J. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes. Curr Hematol Rep. 2005 May.4(3):175-181. Pubmedid: [15865868](https://www.ncbi.nlm.nih.gov/pubmed/15865868). 
    * Komrokji R, Oliva J, Zand M, Felgar R, Abboud C. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol. 2005 Jul.79(3):211-215. Pubmedid: [15981226](https://www.ncbi.nlm.nih.gov/pubmed/15981226). 
    * Bennett J, Komrokji R. The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment. Hematology. 2005.10:258-269. Pubmedid: [16188686](https://www.ncbi.nlm.nih.gov/pubmed/16188686). 
    * Komrokji R, Lyman G. The colony-stimulating factors: use to prevent and treat neutropenia and its complications. Expert Opin Biol Ther. 2004 Dec.4(12):1897-1910. Pubmedid: [15571452](https://www.ncbi.nlm.nih.gov/pubmed/15571452). 
    * Komrokji R, Ifthikharuddin J, Felgar R, Abboud C, Wedow L, Connaughton A, Bennett J. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review. Am J Hematol. 2004 Aug.76(4):389-394. Pubmedid: [15282676](https://www.ncbi.nlm.nih.gov/pubmed/15282676). 
    * Komrokji R, Bennett J. The myelodysplastic syndromes: classification and prognosis. Curr Hematol Rep. 2003 May.2(3):179-185. Pubmedid: [12901338](https://www.ncbi.nlm.nih.gov/pubmed/12901338). 
  * ## Grants
    * Title: Use Machine Learning to Identify Novel Image-Based Markers That Can Distinguish Between ICUS, CCUS, and MDS and Aid in the Prediction of Disease Evolution, Survival, and Genetic Evolution in Patients with Pre-MDS Condition and MDS  
Award Number:   
Sponsor: THE EDWARD P. EVANS FOUNDATION  
El N. (PD/PI), Komrokji, R. (Co-PD/PI)
    * Title: Myeloproliferative Neoplasms-Research Consortium  
Award Number: 2P01CA108671-15  
Sponsor: National Cancer Institute (NCI)  
Komrokji, R. (PD/PI)


## Find a Researcher Search
Program Select Cancer Biology and Evolution Program Cancer Epidemiology Program Molecular Medicine Program Health Outcomes & Behavior Program Immuno-Oncology Non-Programmatically Aligned
Department Select BioEngineering Biostatistics and Bioinformatics Cancer Epidemiology Metabolism and Physiology Drug Discovery Health Outcomes & Behavior Immunology Integrated Mathematical Oncology Machine Learning Molecular Oncology Tumor Microenvironment and Metastasis
Center of Excellence Select Center for Infection Research in Cancer DeBartolo Family Personalized Medicine Institute Evolutionary Therapy Lung Cancer Center of Excellence Melanoma Research Center of Excellence
Work Group Select Cancer Chemoprevention Research Interest Group Myeloma Systems Medicine Working Group Tobacco Research & Intervention Program
Keyword
Search
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center") [ ![](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-mobile-white.svg) ](https://www.moffitt.org/ "Logo for Moffitt Cancer Center")
Our Mission
To contribute to the prevention and cure of cancer.
[Connect with a Cancer Expert](https://www.moffitt.org/eforms/patientregistrationform/)
[ ![Designated Comprehensive Cancer Center](https://www.moffitt.org/globalassets/images/logos/nci.png) ](https://www.moffitt.org/about-moffitt/nci-designation/?source=footer "Designated Comprehensive Cancer Center") [ ![Florida Health Cancer Center of Excellence](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/moffitt-cancer-center-of-excellence-2.png) ](https://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html "Florida Health Cancer Center of Excellence") [ ![Magnet Recognized](https://www.moffitt.org/globalassets/images/logos/magnet.png) ](https://www.moffitt.org/about-moffitt/medical/nursing/?source=footer "Magnet Recognized") [ ![National Comprehensive Cancer Network](https://www.moffitt.org/globalassets/global-blocks/navigation/footer/nccn.png) ](https://www.nccn.org/patients/ "National Comprehensive Cancer Network")
Careers
    * [Careers at Moffitt](https://www.moffitt.org/careers/)
    * [Search Jobs](https://moffitt-cancer-center-careers.hctsportals.com/)
    * [Training & Education](https://www.moffitt.org/education/)


Emerging Cancer Therapies
    * [CAR T Therapy](https://www.moffitt.org/treatments/immunotherapy/car-t-therapy/)
    * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/)
    * [TIL Therapy](https://www.moffitt.org/treatments/immunotherapy/til-therapy/)


Cancers & Treatments
    * [Cancers We Treat](https://www.moffitt.org/cancers/)
    * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/)
    * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/)
    * [Treatments We Offer](https://www.moffitt.org/treatments/)


Get Involved
    * [Donate](https://fundraise.moffitt.org/give/563959/#!/donation/checkout)
    * [Volunteer](https://www.moffitt.org/give/get-involved/volunteer-your-time/)
    * [Ways to Give](https://www.moffitt.org/give/ways-to-give/)


Cancer Screening
    * [Head and Neck Cancer Screening](https://www.moffitt.org/diagnostic-services/cancer-screenings/head-and-neck-cancer-screening/)
    * [Lung CT Screening](https://www.moffitt.org/cancers/lung-cancer/lung-cancer-screening-and-surveillance-program/)
    * [Mammogram](https://www.moffitt.org/cancers/breast-cancer/diagnosis/screening/mammogram/)
    * [Skin Cancer Mole Patrol](https://www.moffitt.org/diagnostic-services/cancer-screenings/mole-patrol/)


Patients & Family
    * [Appointments](https://www.moffitt.org/eforms/patientregistrationform/)
    * [Find a Doctor](https://www.moffitt.org/find-a-doctor/)
    * [Insurance & Financial Info](https://www.moffitt.org/patient-family/insurance-financial-information/)
    * [Moffitt Blog for Patients](https://www.moffitt.org/taking-care-of-your-health/)
    * [Patient & Family Resources](https://www.moffitt.org/patient-family/)


About Moffitt
    * [About](https://www.moffitt.org/about-moffitt/)
    * [Community Benefit](https://www.moffitt.org/publications/community-benefit/)
    * [Patient Outcomes](https://www.moffitt.org/about-moffitt/outcomes/)
    * [Research](https://www.moffitt.org/research-science/)


Industry Partnerships
    * [Available Emerging Technologies](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/available-technologies/)
    * [Business of Biotech](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/business-of-biotech/)
    * [Cell Therapy Facility](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/cell-therapy-gene-engineering/)
    * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/)


Resources
    * [Calendar of Events](https://www.moffitt.org/calendar/)
    * [Endeavor](https://www.moffitt.org/endeavor/)
    * [Newsroom](https://www.moffitt.org/newsroom/)
    * [Partnerships](https://www.moffitt.org/about-moffitt/strategic-alliances-and-partnerships/)
    * [Publications](https://www.moffitt.org/publications/)


Call Today
[1-888-663-3488](tel:1-888-663-3488 "Call Today")
[ ](https://www.facebook.com/MoffittCancerCenter "Facebook") [ ](https://twitter.com/MoffittNews "Twitter") [ ](https://www.instagram.com/moffittcancercenter/ "Instagram") [ ](https://www.youtube.com/user/MoffittNews "YouTube")
[ Getting Here ](https://www.moffitt.org/locations-directions/) [ Patient Portal ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/) [ Refer a Patient ](https://www.moffitt.org/eforms/referapatient/) [ Provider Portal ](https://rpp.moffitt.org/) [ Staff Login ](https://hlmconnect.moffitt.org/dana-na/auth/url_default/welcome.cgi?source=footer&_ga=2.192849257.2128654650.1660063894-1522311918.1659049215)
  * [Privacy Policy](https://www.moffitt.org/legal-statements-and-policies/privacy-policy/)
  * [Terms & Conditions](https://www.moffitt.org/terms-conditions/ "Terms & Condition")
  * [Unsubscribe](https://www.moffitt.org/eforms/unsubscribe/ "Unsubscribe")
  * [State Nonprofit Disclosures](https://www.moffitt.org/globalassets/pdfs/footer/state-registration-for-web.pdf "State Nonprofit Disclosures")
  * [Donor Privacy](https://www.moffitt.org/give/donor-privacy/ "Donor Privacy")
  * [Notice of Privacy Practices](https://www.moffitt.org/legal-statements-and-policies/notice-of-privacy-practices/ "Notice of Privacy Practices")
  * [Visitor Policy](https://www.moffitt.org/globalassets/pdfs/patient--family/preparing-for-your-appointment/visitation-and-family-presence-policy.pdf "Visitor Policy")
  * [Moffitt Masking Policy](https://www.moffitt.org/globalassets/pdfs/footer/ic-085-moffitt-masking-policy.pdf)
  * [Price Transparency](https://eforms.moffitt.org/Moffittcancercenter_standardcharges/593238634_H.-Lee-Moffitt-Cancer-Center-and-Research-Institute-Hospital,-Inc._standardcharges.json)
  * [Sitemap](https://www.moffitt.org/sitemap.xml)


©Copyright 2025 Moffitt Cancer Center
Discover More
  * [Individualized Cancer Treatment in Florida](https://moffitt.org/patient-family/)
  * [Cancer Second Opinion Appointment in Florida](https://moffitt.org/diagnostic-services/second-opinion/)
  * [Cancer Healthcare Professionals in Florida](https://moffitt.org/for-healthcare-professionals/)


### Cambiar el idioma
Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al [1-888-663-3488](tel:1-888-663-3488).
Gracias.
[Cancel | Cancelar](https://www.moffitt.org/research-science/researchers/rami-komrokji) [OK](https://www.moffitt.org/research-science/researchers/rami-komrokji)
[ ![Moffitt Cancer Center](https://www.moffitt.org/globalassets/images/logos/moffitt-logo-full-white.svg) ](https://www.moffitt.org/ "Moffitt Cancer Center")
Search
Menu
  * [Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/rami-komrokji) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)
  * [Patients & Families](https://www.moffitt.org/research-science/researchers/rami-komrokji) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/rami-komrokji) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-31)
  * [Research](https://www.moffitt.org/research-science/researchers/rami-komrokji) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)
  * [Training & Education](https://www.moffitt.org/research-science/researchers/rami-komrokji) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)
  * [Give](https://www.moffitt.org/research-science/researchers/rami-komrokji) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-63)


Schedule
[New Patients](https://www.moffitt.org/eforms/patientregistrationform/ "New Patients") [Referring Physicians](https://www.moffitt.org/eforms/referapatient/ "Referring Physicians")
[ Find a Doctor ](https://www.moffitt.org/find-a-doctor/ "Find a Doctor")
Patient Portal
[Log In](https://mymoffitt.iqhealth.com/ "Log In") [Enroll](https://mymoffitt.iqhealth.com/self-enroll/)
[ Careers ](https://www.moffitt.org/careers/ "Careers")
[ Locations ](https://www.moffitt.org/locations-directions/ "Locations")
[ 1-888-663-3488 ](tel:1-888-663-3488 "Call 1-888-663-3488")
English
[English](https://www.moffitt.org/research-science/researchers/rami-komrokji/ "English") [Spanish](https://www.moffitt.org/es/research-science/researchers/rami-komrokji/ "Spanish")
[ ](https://www.moffitt.org/research-science/researchers/?campaign=567103 "Donate")
[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)[Cancer Types & Treatments](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)
  * [ Cancers ](https://www.moffitt.org/cancers/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-5)
  * [ Treatments ](https://www.moffitt.org/treatments/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-7)
  * [ Clinical Trials ](https://www.moffitt.org/clinical-trials-research/clinical-trials/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-9)
  * [ Diagnostic Services ](https://www.moffitt.org/diagnostic-services/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-11)


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)[Cancers](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)
  * [Acute Lymphocytic Leukemia (ALL)](https://www.moffitt.org/cancers/acute-lymphocytic-leukemia-all/ "Acute Lymphocytic Leukemia \(ALL\)")
  * [Acute Myeloid Leukemia (AML)](https://www.moffitt.org/cancers/acute-myelogenous-leukemia/ "Acute Myeloid Leukemia \(AML\)")
  * [Acute Promyelocytic Leukemia (APL)](https://www.moffitt.org/cancers/acute-promyelocytic-leukemia-apl/ "Acute Promyelocytic Leukemia \(APL\)")
  * [Adrenal Cancer](https://www.moffitt.org/cancers/adrenal-cancer/ "Adrenal Cancer")
  * [Anal Cancer](https://www.moffitt.org/cancers/anal-cancer/ "Anal Cancer")
  * [Appendiceal (Appendix) Cancer](https://www.moffitt.org/cancers/appendiceal-appendix-cancer/ "Appendiceal \(Appendix\) Cancer")
  * [Astrocytoma](https://www.moffitt.org/cancers/astrocytoma/ "Astrocytoma")
  * [Basal Cell Carcinoma](https://www.moffitt.org/cancers/basal-cell-carcinoma/ "Basal Cell Carcinoma")
  * [Bladder Cancer](https://www.moffitt.org/cancers/bladder-cancer/ "Bladder Cancer")
  * [Bone Metastasis](https://www.moffitt.org/cancers/bone-metastasis/ "Bone Metastasis")
  * [Brain Cancer](https://www.moffitt.org/cancers/brain-cancer/ "Brain Cancer")
  * [Brain Tumor](https://www.moffitt.org/cancers/brain-tumor/ "Brain Tumor")
  * [Brain Metastases](https://www.moffitt.org/cancers/brain-metastases/ "Brain Metastases")
  * [Breast Cancer](https://www.moffitt.org/cancers/breast-cancer/ "Breast Cancer")
  * [Cervical Cancer](https://www.moffitt.org/cancers/cervical-cancer/ "Cervical Cancer")
  * [Cholangiocarcinoma (Bile Duct Cancer)](https://www.moffitt.org/cancers/cholangiocarcinoma-bile-duct-cancer/ "Cholangiocarcinoma \(Bile Duct Cancer\)")
  * [Chronic Lymphocytic Leukemia (CLL)](https://www.moffitt.org/cancers/chronic-lymphocytic-leukemia/ "Chronic Lymphocytic Leukemia \(CLL\)")
  * [Colon Cancer](https://www.moffitt.org/cancers/colon-cancer/ "Colon Cancer")
  * [Colorectal Cancer](https://www.moffitt.org/cancers/colorectal-cancer/ "Colorectal Cancer")
  * [Chronic Myeloid Leukemia (CML)](https://www.moffitt.org/cancers/chronic-myelogenous-leukemia-cml/ "Chronic Myeloid Leukemia \(CML\)")
  * [Cutaneous Lymphoma (CTCL)](https://www.moffitt.org/cancers/cutaneous-t-cell-lymphoma/ "Cutaneous Lymphoma \(CTCL\)")
  * [Diffuse Large B-Cell Lymphoma](https://www.moffitt.org/cancers/diffuse-large-b-cell-lymphoma/ "Diffuse Large B-Cell Lymphoma")
  * [Ductal Carcinoma In Situ](https://www.moffitt.org/cancers/ductal-carcinoma-in-situ/ "Ductal Carcinoma In Situ")
  * [Endometrial (Uterine) Cancer](https://www.moffitt.org/cancers/endometrial-uterine-cancer/ "Endometrial \(Uterine\) Cancer")
  * [Esophageal Cancer](https://www.moffitt.org/cancers/esophageal-cancer/ "Esophageal Cancer")
  * [Follicular Lymphoma](https://www.moffitt.org/cancers/follicular-lymphoma/ "Follicular Lymphoma")
  * [Gallbladder Cancer](https://www.moffitt.org/cancers/gallbladder-cancer/ "Gallbladder Cancer")
  * [Gastrointestinal Carcinoid Tumor](https://www.moffitt.org/cancers/gastrointestinal-carcinoid-tumor/ "Gastrointestinal Carcinoid Tumor")
  * [GIST (Gastrointestinal Stromal Tumor)](https://www.moffitt.org/cancers/gist-gastrointestinal-stromal-tumor/ "GIST \(Gastrointestinal Stromal Tumor\)")
  * [Glioblastoma](https://www.moffitt.org/cancers/glioblastoma/ "Glioblastoma")
  * [Head and Neck Cancer](https://www.moffitt.org/cancers/head-and-neck-cancer/ "Head and Neck Cancer")
  * [HER2 Positive Breast Cancer](https://www.moffitt.org/cancers/her2-positive-breast-cancer/ "HER2 Positive Breast Cancer")
  * [Hodgkin Lymphoma](https://www.moffitt.org/cancers/hodgkin-lymphoma/ "Hodgkin Lymphoma")
  * [Inflammatory Breast Cancer](https://www.moffitt.org/cancers/inflammatory-breast-cancer/ "Inflammatory Breast Cancer")
  * [Invasive Ductal Carcinoma](https://www.moffitt.org/cancers/invasive-ductal-carcinoma/ "Invasive Ductal Carcinoma")
  * [Kidney (Renal Cell) Cancer](https://www.moffitt.org/cancers/kidney-renal-cell-cancer/ "Kidney \(Renal Cell\) Cancer")
  * [Leukemia](https://www.moffitt.org/cancers/leukemia/ "Leukemia")
  * [Liver (Hepatocellular) Cancer](https://www.moffitt.org/cancers/liver-hepatocellular-cancer/ "Liver \(Hepatocellular\) Cancer")
  * [Low-Grade Glioma](https://www.moffitt.org/cancers/low-grade-glioma/ "Low-Grade Glioma")
  * [Lung Cancer](https://www.moffitt.org/cancers/lung-cancer/ "Lung Cancer")
  * [Lymphomas (Hodgkin and Non-Hodgkin)](https://www.moffitt.org/cancers/lymphomas-hodgkin-and-non-hodgkin/ "Lymphomas \(Hodgkin and Non-Hodgkin\)")
  * [Mantle Cell Lymphoma](https://www.moffitt.org/cancers/mantle-cell-lymphoma/ "Mantle Cell Lymphoma")
  * [Melanoma](https://www.moffitt.org/cancers/melanoma/ "Melanoma")
  * [Meningioma](https://www.moffitt.org/cancers/meningioma/ "Meningioma")
  * [Merkel Cell Carcinoma](https://www.moffitt.org/cancers/merkel-cell-carcinoma/ "Merkel Cell Carcinoma")
  * [Mesothelioma](https://www.moffitt.org/cancers/mesothelioma/ "Mesothelioma")
  * [Metastatic Breast Cancer](https://www.moffitt.org/cancers/metastatic-breast-cancer/ "Metastatic Breast Cancer")
  * [Monoclonal Gammopathy of Undetermined Significance (MGUS)](https://www.moffitt.org/cancers/monoclonal-gammopathy-of-undetermined-significance-mgus/ "Monoclonal Gammopathy of Undetermined Significance \(MGUS\)")
  * [Multiple Myeloma-Plasma Cell Tumor](https://www.moffitt.org/cancers/multiple-myeloma-plasma-cell-tumor/ "Multiple Myeloma-Plasma Cell Tumor")
  * [Myelodysplastic Syndromes (MDS)](https://www.moffitt.org/cancers/myelodysplastic-syndromes-mds/ "Myelodysplastic Syndromes \(MDS\)")
  * [Neuroendocrine Tumor](https://www.moffitt.org/cancers/neuroendocrine-tumor/ "Neuroendocrine Tumor")
  * [Neurofibromatosis](https://www.moffitt.org/cancers/neurofibromatosis/ "Neurofibromatosis")
  * [Non-Hodgkin Lymphoma](https://www.moffitt.org/cancers/non-hodgkin-lymphoma/ "Non-Hodgkin Lymphoma")
  * [Oral Cavity (Mouth) Cancer](https://www.moffitt.org/cancers/oral-cavity-mouth-cancer/ "Oral Cavity \(Mouth\) Cancer")
  * [Insurance and Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/ "Insurance and Financial Information")
  * [Oral Cavity or Throat Cancer](https://www.moffitt.org/cancers/oral-cavity-or-throat-cancer/ "Oral Cavity or Throat Cancer")
  * [Osteosarcoma](https://www.moffitt.org/cancers/osteosarcoma/ "Osteosarcoma")
  * [Ovarian Cancer](https://www.moffitt.org/cancers/ovarian-cancer/ "Ovarian Cancer")
  * [Pancoast Tumor](https://www.moffitt.org/cancers/pancoast-tumor/ "Pancoast Tumor")
  * [Pancreatic Cancer](https://www.moffitt.org/cancers/pancreatic-cancer/ "Pancreatic Cancer")
  * [Penile Cancer](https://www.moffitt.org/cancers/penile-cancer/ "Penile Cancer")
  * [Pituitary Adenoma](https://www.moffitt.org/cancers/pituitary-adenoma/ "Pituitary Adenoma")
  * [Prostate Cancer](https://www.moffitt.org/cancers/prostate-cancer/ "Prostate Cancer")
  * [Rectal Cancer](https://www.moffitt.org/cancers/rectal-cancer/ "Rectal Cancer")
  * [Sarcoma](https://www.moffitt.org/cancers/sarcoma/ "Sarcoma")
  * [Skin Cancer (Nonmelanoma)](https://www.moffitt.org/cancers/skin-cancer-nonmelanoma/ "Skin Cancer \(Nonmelanoma\)")
  * [Skull Base Tumors](https://www.moffitt.org/cancers/skull-base-tumors/ "Skull Base Tumors")
  * [Small Intestine Cancer](https://www.moffitt.org/cancers/small-intestine-cancer/ "Small Intestine Cancer")
  * [Spinal Tumor](https://www.moffitt.org/cancers/spinal-tumor/ "Spinal Tumor")
  * [Squamous Cell Carcinoma](https://www.moffitt.org/cancers/squamous-cell-carcinoma/ "Squamous Cell Carcinoma")
  * [Smoldering Multiple Myeloma](https://www.moffitt.org/cancers/smoldering-multiple-myeloma-smm/ "Smoldering Multiple Myeloma")
  * [Stomach (Gastric) Cancer](https://www.moffitt.org/cancers/stomach-gastric-cancer/ "Stomach \(Gastric\) Cancer")
  * [Testicular Cancer](https://www.moffitt.org/cancers/testicular-cancer/ "Testicular Cancer")
  * [Throat Cancer](https://www.moffitt.org/cancers/throat-cancer/ "Throat Cancer")
  * [Thymoma](https://www.moffitt.org/cancers/thymoma/ "Thymoma")
  * [Thyroid Cancer](https://www.moffitt.org/cancers/thyroid-cancer/ "Thyroid Cancer")
  * [Tongue Cancer](https://www.moffitt.org/cancers/tongue-cancer/ "Tongue Cancer")
  * [Tracheal Cancer](https://www.moffitt.org/cancers/tracheal-cancer/ "Tracheal Cancer")
  * [Triple Negative Breast Cancer](https://www.moffitt.org/cancers/triple-negative-breast-cancer/ "Triple Negative Breast Cancer")
  * [Vaginal Cancer](https://www.moffitt.org/cancers/vaginal-cancer/ "Vaginal Cancer")
  * [Vulvar Cancer](https://www.moffitt.org/cancers/vulvar-cancer/ "Vulvar Cancer")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)[Treatments](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)
  * [Blood Bone Marrow Transplant](https://www.moffitt.org/treatments/blood-bone-marrow-transplant/ "Blood Bone Marrow Transplant")
  * [Bloodless Medicine and Surgery](https://www.moffitt.org/treatments/bloodless-medicine-and-surgery/ "Bloodless Medicine and Surgery")
  * [Cardio-Oncology](https://www.moffitt.org/treatments/cardio-oncology/ "Cardio-Oncology")
  * [Chemotherapy](https://www.moffitt.org/treatments/chemotherapy/ "Chemotherapy")
  * [Clinical Pathways](https://www.moffitt.org/treatments/clinical-pathways/ "Clinical Pathways")
  * [Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/ "Clinical Trials")
  * [Diagnostic Services](https://www.moffitt.org/diagnostic-services/ "Diagnostic Services")
  * [Endoscopic Procedures](https://www.moffitt.org/treatments/endoscopic-procedures/ "Endoscopic Procedures")
  * [Fertility Preservation](https://www.moffitt.org/treatments/fertility-preservation/ "Fertility Preservation")
  * [Gynecologic Oncology](https://www.moffitt.org/treatments/gynecologic-oncology/ "Gynecologic Oncology")
  * [Immunotherapy](https://www.moffitt.org/treatments/immunotherapy/ "Immunotherapy")
  * [Interventional Pain Management](https://www.moffitt.org/treatments/interventional-pain-management/ "Interventional Pain Management")
  * [Interventional Radiology](https://www.moffitt.org/treatments/interventional-radiology/ "Interventional Radiology")
  * [Precision Medicine](https://www.moffitt.org/treatments/precision-medicine/ "Precision Medicine")
  * [Pharmacy](https://www.moffitt.org/treatments/pharmacy/ "Pharmacy")
  * [Radiation Therapy](https://www.moffitt.org/treatments/radiation-therapy/ "Radiation Therapy")
  * [Rehabilitation Services](https://www.moffitt.org/treatments/rehabilitation-services/ "Rehabilitation Services")
  * [Supportive Care Medicine](https://www.moffitt.org/treatments/supportive-care-medicine/ "Supportive Care Medicine")
  * [Surgical Care](https://www.moffitt.org/treatments/surgical-care/ "Surgical Care")
  * [Systemic Therapy](https://www.moffitt.org/treatments/systemic-therapy/ "Systemic Therapy")
  * [Targeted Therapy](https://www.moffitt.org/treatments/targeted-therapy/ "Targeted Therapy")
  * [Tumor Board](https://www.moffitt.org/treatments/tumor-board/ "Tumor Board")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)[Clinical Trials](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)
  * [Am I A Candidate?](https://www.moffitt.org/clinical-trials-research/clinical-trials/am-i-a-candidate/ "Am I A Candidate?")
  * [Clinical Research Unit](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-research-unit/ "Clinical Research Unit")
  * [Clinical Trials Administration](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-administration/ "Clinical Trials Administration")
  * [Clinical Trials: Are They Right for You?](https://www.moffitt.org/clinical-trials-research/clinical-trials/clinical-trials-are-they-right-for-you/ "Clinical Trials: Are They Right for You?")
  * [Patient Protection](https://www.moffitt.org/clinical-trials-research/clinical-trials/patient-protection/ "Patient Protection")
  * [Phase 1 Clinical Trials](https://www.moffitt.org/clinical-trials-research/clinical-trials/phase-1-clinical-trials/ "Phase 1 Clinical Trials")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)[Diagnostic Services](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-3)
  * [Cancer Screenings](https://www.moffitt.org/diagnostic-services/cancer-screenings/ "Cancer Screenings")
  * [Genetic Counseling and Genetic Testing](https://www.moffitt.org/diagnostic-services/genetic-counseling-and-genetic-testing/ "Genetic Counseling and Genetic Testing")
  * [Labwork and Bloodwork](https://www.moffitt.org/diagnostic-services/labwork-and-bloodwork/ "Labwork and Bloodwork")
  * [Pathology](https://www.moffitt.org/diagnostic-services/pathology/ "Pathology")
  * [Radiology – Diagnostic Imaging and Interventional Radiology](https://www.moffitt.org/diagnostic-services/radiology-diagnostic-imaging-and-interventional-radiology/ "Radiology – Diagnostic Imaging and Interventional Radiology")
  * [Cancer Treatments](https://www.moffitt.org/treatments/ "Cancer Treatments")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)[Patients & Families](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)
  * [ Patient & Family ](https://www.moffitt.org/patient-family/)
  * [ Preparing For Your Appointment ](https://www.moffitt.org/patient-family/preparing-for-your-appointment/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-15)
  * [ Insurance & Financial Information ](https://www.moffitt.org/patient-family/insurance-financial-information/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-17)
  * [ Programs & Support Services ](https://www.moffitt.org/patient-family/programs-support-services/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-19)
  * [ Patient and Family Centered Care ](https://www.moffitt.org/patient-family/patient-and-family-centered-care/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-21)
  * [ Cancer Survivorship ](https://www.moffitt.org/patient-family/cancer-survivorship/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-23)
  * [ International Patient Services ](https://www.moffitt.org/patient-family/international-patient-services/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-25)
  * [ Moffitt Virtual Care ](https://www.moffitt.org/patient-family/moffitt-virtual-care/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-27)
  * [ Inspiring Stories ](https://www.moffitt.org/inspiring-stories/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-29)


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)[Preparing For Your Appointment](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [Patient and Family Orientation](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-and-family-orientation/ "Patient and Family Orientation")
  * [Medical Records](https://www.moffitt.org/patient-family/preparing-for-your-appointment/medical-records/ "Medical Records")
  * [Appointment Reminder Service](https://www.moffitt.org/patient-family/preparing-for-your-appointment/appointment-reminder-service/ "Appointment Reminder Service")
  * [MyMoffitt Patient Portal](https://www.moffitt.org/patient-family/preparing-for-your-appointment/mymoffitt-patient-portal/ "MyMoffitt Patient Portal")
  * [New Cancer Diagnosis](https://www.moffitt.org/patient-family/preparing-for-your-appointment/new-cancer-diagnosis/ "New Cancer Diagnosis")
  * [Online Registration Frequently Asked Questions](https://www.moffitt.org/patient-family/preparing-for-your-appointment/online-registration-frequently-asked-questions/ "Online Registration Frequently Asked Questions")
  * [Scheduling Your Appointment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/scheduling-your-appointment/ "Scheduling Your Appointment")
  * [Traveling for Cancer Treatment](https://www.moffitt.org/patient-family/preparing-for-your-appointment/traveling-for-cancer-treatment/ "Traveling for Cancer Treatment")
  * [Preparing For Your Hospitalization](https://www.moffitt.org/patient-family/preparing-for-your-hospitalization/ "Preparing For Your Hospitalization")
  * [Preparing For Your Surgery](https://www.moffitt.org/patient-family/preparing-for-your-surgery/ "Preparing For Your Surgery")
  * [Visitor Policy](https://www.moffitt.org/patient-family/preparing-for-your-appointment/visitor-policy/ "Visitor Policy")
  * [Patient Rights and Responsibilities](https://www.moffitt.org/patient-family/preparing-for-your-appointment/patient-rights-and-responsibilities/ "Patient Rights and Responsibilities")
  * [What to Know About Your Appointments During Hurricane Season](https://www.moffitt.org/patient-family/hurricane/appointments-during-hurricane-season/ "What to Know About Your Appointments During Hurricane Season")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)[Insurance & Financial Information](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [Copay Assistance Program](https://www.moffitt.org/patient-family/insurance-financial-information/copay-assistance-program/ "Copay Assistance Program")
  * [Financial Assistance](https://www.moffitt.org/patient-family/insurance-financial-information/financial-assistance/ "Financial Assistance")
  * [Glossary of Terms](https://www.moffitt.org/patient-family/insurance-financial-information/glossary-of-terms/ "Glossary of Terms")
  * [Health Exchange](https://www.moffitt.org/patient-family/insurance-financial-information/health-exchange/ "Health Exchange")
  * [Insurance Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/insurance-coverage/ "Insurance Coverage")
  * [Medicare Coverage](https://www.moffitt.org/patient-family/insurance-financial-information/medicare-coverage/ "Medicare Coverage")
  * [Obtain a Cost Estimate](https://www.moffitt.org/patient-family/insurance-financial-information/obtain-a-cost-estimate/ "Obtain a Cost Estimate")
  * [Questions to Ask Your Insurance Company](https://www.moffitt.org/patient-family/insurance-financial-information/questions-to-ask-your-insurance-company/ "Questions to Ask Your Insurance Company")
  * [Understanding Your Bill](https://www.moffitt.org/patient-family/insurance-financial-information/understanding-your-bill/ "Understanding Your Bill")
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/insurance-financial-information/frequently-asked-questions/ "Frequently Asked Questions")
  * [Financial Information](https://www.moffitt.org/patient-family/insurance-financial-information/financial-information/ "Financial Information")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)[Programs & Support Services](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [Advance Care Planning](https://www.moffitt.org/patient-family/programs-support-services/advance-care-planning/ "Advance Care Planning")
  * [AYA: Adolescent Young Adult Program](https://www.moffitt.org/patient-family/programs-support-services/aya-adolescent-young-adult-program/ "AYA: Adolescent Young Adult Program")
  * [Chaplaincy Spiritual Care](https://www.moffitt.org/patient-family/programs-support-services/chaplaincy-spiritual-care/ "Chaplaincy Spiritual Care")
  * [Community Resources](https://www.moffitt.org/patient-family/programs-support-services/online-resources/ "Community Resources")
  * [Counseling and Support](https://www.moffitt.org/patient-family/programs-support-services/counseling-and-support/ "Counseling and Support")
  * [Language Services](https://www.moffitt.org/patient-family/programs-support-services/language-services/ "Language Services")
  * [Nutrition](https://www.moffitt.org/patient-family/programs-support-services/nutrition/ "Nutrition")
  * [Senior Adult Oncology Program](https://www.moffitt.org/patient-family/programs-support-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")
  * [Specialty Pharmacy at Moffitt](https://www.moffitt.org/patient-family/programs-support-services/specialty-pharmacy/ "Specialty Pharmacy at Moffitt")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)[Patient and Family Centered Care](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [Demonstrating Respect at Moffitt](https://www.moffitt.org/patient-family/patient-and-family-centered-care/demonstrating-respect-at-moffitt/ "Demonstrating Respect at Moffitt")
  * [Daisy and Sunflower Awards](https://www.moffitt.org/patient-family/patient-and-family-centered-care/daisy-and-sunflower-awards/ "Daisy and Sunflower Awards")
  * [Patient and Family Advisory Program](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-and-family-advisory-program/ "Patient and Family Advisory Program")
  * [Patient Relations](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-relations/ "Patient Relations")
  * [Patient Researcher Forum](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patient-researcher-forum/ "Patient Researcher Forum")
  * [Patti K Halula Legacy Award](https://www.moffitt.org/patient-family/patient-and-family-centered-care/patti-k-halula-legacy-award/ "Patti K Halula Legacy Award")
  * [Share Gratitude for Moffitt Team Members](https://www.moffitt.org/patient-family/patient-and-family-centered-care/share-gratitude-for-moffitt-team-members/ "Share Gratitude for Moffitt Team Members")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)[Cancer Survivorship](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [Cancer Survivorship Program](https://www.moffitt.org/patient-family/cancer-survivorship/cancer-survivorship-program/ "Cancer Survivorship Program")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)[International Patient Services](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [Frequently Asked Questions](https://www.moffitt.org/patient-family/international-patient-services/frequently-asked-questions/ "Frequently Asked Questions")
  * [Online Consult Forms](https://www.moffitt.org/patient-family/international-patient-services/online-consult-forms/ "Online Consult Forms")
  * [Online Consults](https://www.moffitt.org/patient-family/international-patient-services/online-consults/ "Online Consults")
  * [Moffitt Outreach in Puerto Rico](https://www.moffitt.org/patient-family/international-patient-services/puerto-rico/ "Moffitt Outreach in Puerto Rico")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)[Moffitt Virtual Care](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [All About Virtual Care](https://www.moffitt.org/patient-family/moffitt-virtual-care/all-about-virtual-care/ "All About Virtual Care")
  * [Informed Consent for Telemedicine](https://www.moffitt.org/patient-family/moffitt-virtual-care/informed-consent-for-telemedicine/ "Informed Consent for Telemedicine")
  * [New Cancer Patients](https://www.moffitt.org/patient-family/moffitt-virtual-care/new-cancer-patients/ "New Cancer Patients")
  * [Virtual Care Success Checklist](https://www.moffitt.org/patient-family/moffitt-virtual-care/virtual-care-success-checklist/ "Virtual Care Success Checklist")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)[Inspiring Stories](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-13)
  * [Isabel's Story](https://www.moffitt.org/inspiring-stories/isabels-story/ "Isabel's Story")
  * [Amanda's Story](https://www.moffitt.org/inspiring-stories/amandas-story/ "Amanda's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story-my-prostate-cancer-journey/ "Rick's Story")
  * [Vondalyn's Story: From Adversity to Advocacy](https://www.moffitt.org/inspiring-stories/vondalyns-story-from-adversity-to-advocacy/ "Vondalyn's Story: From Adversity to Advocacy")
  * [Cayla’s Story: Cancer Never Cares About Anything Like That](https://www.moffitt.org/inspiring-stories/caylas-story-cancer-never-cares-about-anything-like-that/ "Cayla’s Story: Cancer Never Cares About Anything Like That")
  * [Rick's Story: Now What?](https://www.moffitt.org/inspiring-stories/ricks-story-now-what/ "Rick's Story: Now What?")
  * [Amy's Story: No Longer Alone](https://www.moffitt.org/inspiring-stories/no-longer-alone/ "Amy's Story: No Longer Alone")
  * [Zoe's Story](https://www.moffitt.org/inspiring-stories/zoeys-story/ "Zoe's Story")
  * [Erma's Story](https://www.moffitt.org/inspiring-stories/ermas-story/ "Erma's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donnas-story/ "Donna's Story")
  * [Dr. Vadaparampil's Story](https://www.moffitt.org/inspiring-stories/dr.-vadaparampils-story "Dr. Vadaparampil's Story")
  * [Mark's Story](https://www.moffitt.org/inspiring-stories/marks-story/ "Mark's Story")
  * [Heather's Story](https://www.moffitt.org/inspiring-stories/heathers-story/ "Heather's Story")
  * [Ellen's Story](https://www.moffitt.org/inspiring-stories/ellens-story/ "Ellen's Story")
  * [Dr. Tran's Story](https://www.moffitt.org/inspiring-stories/dr.-trans-story "Dr. Tran's Story")
  * [Dr. Toloza's Story](https://www.moffitt.org/inspiring-stories/dr.-tolozas-story "Dr. Toloza's Story")
  * [Dr. Silva's Story](https://www.moffitt.org/inspiring-stories/dr.-silvas-story "Dr. Silva's Story")
  * [Dr. Fernandez's Story](https://www.moffitt.org/inspiring-stories/dr.-fernandezs-story "Dr. Fernandez's Story")
  * [Dr. Robinson's Story](https://www.moffitt.org/inspiring-stories/dr.-robinsons-story "Dr. Robinson's Story")
  * [Dr. Pow-Sang's Story](https://www.moffitt.org/inspiring-stories/dr.-pow-sangs-story "Dr. Pow-Sang's Story")
  * [Mike's Volunteer Story](https://www.moffitt.org/inspiring-stories/mikes-volunteer-story/ "Mike's Volunteer Story")
  * [Mike's Story](https://www.moffitt.org/inspiring-stories/mikes-story/ "Mike's Story")
  * [Mary Beth's Story](https://www.moffitt.org/inspiring-stories/mary-beths-story/ "Mary Beth's Story")
  * [Malcolm's Story](https://www.moffitt.org/inspiring-stories/malcolms-story/ "Malcolm's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story2/ "Lori's Story")
  * [Miriam's Story](https://www.moffitt.org/inspiring-stories/miriams-story/ "Miriam's Story")
  * [Nick's Story](https://www.moffitt.org/inspiring-stories/nicks-story/ "Nick's Story")
  * [Nadine's Story](https://www.moffitt.org/inspiring-stories/nadines-story/ "Nadine's Story")
  * [Nancy's Story](https://www.moffitt.org/inspiring-stories/nancys-story/ "Nancy's Story")
  * [Madison's Story](https://www.moffitt.org/inspiring-stories/madisons-story/ "Madison's Story")
  * [Lori's Story](https://www.moffitt.org/inspiring-stories/loris-story/ "Lori's Story")
  * [Lloyd's Story](https://www.moffitt.org/inspiring-stories/lloyds-story/ "Lloyd's Story")
  * [Lanse's Story](https://www.moffitt.org/inspiring-stories/lanses-story/ "Lanse's Story")
  * [Kevin's Story](https://www.moffitt.org/inspiring-stories/kevins-story/ "Kevin's Story")
  * [Dr. Mooney's Story](https://www.moffitt.org/inspiring-stories/dr.-mooneys-story "Dr. Mooney's Story")
  * [Ken's Story](https://www.moffitt.org/inspiring-stories/kens-story/ "Ken's Story")
  * [Dr. Lee's Story](https://www.moffitt.org/inspiring-stories/dr.-lees-story "Dr. Lee's Story")
  * [Dr. Kumar's Story](https://www.moffitt.org/inspiring-stories/dr.-kumars-story "Dr. Kumar's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story2/ "Keith's Story")
  * [Dr. Latifi's Story](https://www.moffitt.org/inspiring-stories/dr.-latifis-story "Dr. Latifi's Story")
  * [Keith's Story](https://www.moffitt.org/inspiring-stories/keiths-story/ "Keith's Story")
  * [Dr. Kubal's Story](https://www.moffitt.org/inspiring-stories/dr.-kubals-story "Dr. Kubal's Story")
  * [Dr. Khakpour's Story](https://www.moffitt.org/inspiring-stories/dr.-khakpours-story "Dr. Khakpour's Story")
  * [Dr. Keenan's Story](https://www.moffitt.org/inspiring-stories/dr.-keenans-story "Dr. Keenan's Story")
  * [Dr. Kanetsky's Story](https://www.moffitt.org/inspiring-stories/dr.-kanetskys-story "Dr. Kanetsky's Story")
  * [Dr. Hoffe's Story](https://www.moffitt.org/inspiring-stories/dr.-hoffes-story "Dr. Hoffe's Story")
  * [Dr. Harrison's Story](https://www.moffitt.org/inspiring-stories/dr.-harrisons-story "Dr. Harrison's Story")
  * [Dr. Gwede's Story](https://www.moffitt.org/inspiring-stories/dr.-gwedes-story "Dr. Gwede's Story")
  * [Dr. Giuliano's Story](https://www.moffitt.org/inspiring-stories/dr.-giulianos-story "Dr. Giuliano's Story")
  * [Juli's Story](https://www.moffitt.org/inspiring-stories/julis-story/ "Juli's Story")
  * [Dr. Gonzalez's Story](https://www.moffitt.org/inspiring-stories/dr.-gonzalezs-story "Dr. Gonzalez's Story")
  * [Dr. Gatenby's Story](https://www.moffitt.org/inspiring-stories/dr.-gatenbys-story "Dr. Gatenby's Story")
  * [Dr. Etame's Story](https://www.moffitt.org/inspiring-stories/dr.-etames-story "Dr. Etame's Story")
  * [Dr. Cleveland's Story](https://www.moffitt.org/inspiring-stories/dr.-clevelands-story "Dr. Cleveland's Story")
  * [John and Whitney's Story](https://www.moffitt.org/inspiring-stories/john-and-whitneys-story/ "John and Whitney's Story")
  * [Liz's Story](https://www.moffitt.org/inspiring-stories/lizs-story/ "Liz's Story")
  * [Meet Lloyd](https://www.moffitt.org/inspiring-stories/meet-lloyd/ "Meet Lloyd")
  * [Paul and Gina's Story](https://www.moffitt.org/inspiring-stories/pauls-and-ginas-story/ "Paul and Gina's Story")
  * [Marvin's Story](https://www.moffitt.org/inspiring-stories/marvins-story/ "Marvin's Story")
  * [Meet Melissa](https://www.moffitt.org/inspiring-stories/meet-melissa/ "Meet Melissa")
  * [Muriel's Story](https://www.moffitt.org/inspiring-stories/muriels-story/ "Muriel's Story")
  * [John's and David's Story](https://www.moffitt.org/inspiring-stories/johns-and-davids-story/ "John's and David's Story")
  * [Melissa's Story](https://www.moffitt.org/inspiring-stories/melissas-story/ "Melissa's Story")
  * [Dr. Alexander Anderson's Story](https://www.moffitt.org/inspiring-stories/dr.-alexander-andersons-story "Dr. Alexander Anderson's Story")
  * [Pam's Story](https://www.moffitt.org/inspiring-stories/pams-story/ "Pam's Story")
  * [Yolanda's Story](https://www.moffitt.org/inspiring-stories/yolandas-story/ "Yolanda's Story")
  * [Wilbur's Story](https://www.moffitt.org/inspiring-stories/wilburs-story/ "Wilbur's Story")
  * [Vikki's Story](https://www.moffitt.org/inspiring-stories/vikkis-story/ "Vikki's Story")
  * [Tiffany's Story](https://www.moffitt.org/inspiring-stories/tiffanys-story/ "Tiffany's Story")
  * [Theresa's Story](https://www.moffitt.org/inspiring-stories/theresas-story/ "Theresa's Story")
  * [Joanna's Story](https://www.moffitt.org/inspiring-stories/joannas-story/ "Joanna's Story")
  * [Jenifer's Story](https://www.moffitt.org/inspiring-stories/jenifers-story/ "Jenifer's Story")
  * [Jeanine's Story](https://www.moffitt.org/inspiring-stories/jeanines-story/ "Jeanine's Story")
  * [Meet Jackie](https://www.moffitt.org/inspiring-stories/meet-jackie/ "Meet Jackie")
  * [Ian's Story](https://www.moffitt.org/inspiring-stories/ians-story/ "Ian's Story")
  * [Howard's Story](https://www.moffitt.org/inspiring-stories/howards-story/ "Howard's Story")
  * [Ryan's Story](https://www.moffitt.org/inspiring-stories/ryans-story/ "Ryan's Story")
  * [Robert's Story](https://www.moffitt.org/inspiring-stories/roberts-story/ "Robert's Story")
  * [Rick's Story](https://www.moffitt.org/inspiring-stories/ricks-story/ "Rick's Story")
  * [Richard's Story](https://www.moffitt.org/inspiring-stories/richards-story/ "Richard's Story")
  * [Rena's Story](https://www.moffitt.org/inspiring-stories/renas-story/ "Rena's Story")
  * [Rebecca's Story](https://www.moffitt.org/inspiring-stories/rebeccas-story/ "Rebecca's Story")
  * [Ray's and Dr. Bui's story](https://www.moffitt.org/inspiring-stories/rays-and-dr.-buis-story "Ray's and Dr. Bui's story")
  * [Patti's Story](https://www.moffitt.org/inspiring-stories/pattis-story/ "Patti's Story")
  * [Pam and Jonathan's story](https://www.moffitt.org/inspiring-stories/pams-and-jonathans-story/ "Pam and Jonathan's story")
  * [Sarah's Story](https://www.moffitt.org/inspiring-stories/sarahs-story/ "Sarah's Story")
  * [Steve and Laura's Story](https://www.moffitt.org/inspiring-stories/steve-and-lauras-story/ "Steve and Laura's Story")
  * [Donna's Story](https://www.moffitt.org/inspiring-stories/donna/ "Donna's Story")
  * [Tommy's Story](https://www.moffitt.org/inspiring-stories/tommys-story/ "Tommy's Story")
  * [Viviana's Story](https://www.moffitt.org/inspiring-stories/vivianas-story/ "Viviana's Story")
  * [Craig's Story](https://www.moffitt.org/inspiring-stories/craigs-story/ "Craig's Story")
  * [William's Story](https://www.moffitt.org/inspiring-stories/williams-story/ "William's Story")
  * [The Wilson - Jones's Family Story](https://www.moffitt.org/inspiring-stories/the-joness-family-story/ "The Wilson - Jones's Family Story")
  * [Woodrow's Story](https://www.moffitt.org/inspiring-stories/woodrows-story/ "Woodrow's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story2/ "Cathy's Story")
  * [Cathy's Story](https://www.moffitt.org/inspiring-stories/cathys-story/ "Cathy's Story")
  * [Carolyn's Story](https://www.moffitt.org/inspiring-stories/carolyn/ "Carolyn's Story")
  * [Beth's Story](https://www.moffitt.org/inspiring-stories/beths-story/ "Beth's Story")
  * [Benita's Story](https://www.moffitt.org/inspiring-stories/benitas-story/ "Benita's Story")
  * [Barney's Story](https://www.moffitt.org/inspiring-stories/barneys-story/ "Barney's Story")
  * [Joel's Story](https://www.moffitt.org/inspiring-stories/joels-story/ "Joel's Story")
  * [Jessica's Story](https://www.moffitt.org/inspiring-stories/jessicas-story/ "Jessica's Story")
  * [Jen's Story](https://www.moffitt.org/inspiring-stories/jens-story/ "Jen's Story")
  * [Jay's Story](https://www.moffitt.org/inspiring-stories/jays-story/ "Jay's Story")
  * [Janelle's Story](https://www.moffitt.org/inspiring-stories/janelles-story/ "Janelle's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story2/ "Greg's Story")
  * [Gayle's Story](https://www.moffitt.org/inspiring-stories/gayles-story/ "Gayle's Story")
  * [Francis' Story](https://www.moffitt.org/inspiring-stories/francis-story/ "Francis' Story")
  * [Dr. Lau's Story](https://www.moffitt.org/inspiring-stories/dr.-laus-story "Dr. Lau's Story")
  * [Dr. Roberto Diaz's Story](https://www.moffitt.org/inspiring-stories/dr.-roberto-diazs-story "Dr. Roberto Diaz's Story")
  * [Dimas' Story](https://www.moffitt.org/inspiring-stories/dimas-story/ "Dimas' Story")
  * [David and Vesta's Story](https://www.moffitt.org/inspiring-stories/david-and-vestas-story/ "David and Vesta's Story")
  * [Cydney's Story](https://www.moffitt.org/inspiring-stories/cydneys-story/ "Cydney's Story")
  * [Charles' Story](https://www.moffitt.org/inspiring-stories/charless-story/ "Charles' Story")
  * [Cammie's Story](https://www.moffitt.org/inspiring-stories/cammies-story/ "Cammie's Story")
  * [Joanne's Story](https://www.moffitt.org/inspiring-stories/joannes-story/ "Joanne's Story")
  * [Neisha's Story](https://www.moffitt.org/inspiring-stories/neishas-story/ "Neisha's Story")
  * [Greg's Story](https://www.moffitt.org/inspiring-stories/gregs-story/ "Greg's Story")
  * [Joshua's Story](https://www.moffitt.org/inspiring-stories/joshuas-story/ "Joshua's Story")
  * [Bridget's Story](https://www.moffitt.org/inspiring-stories/bridgets-story/ "Bridget's Story")
  * [Barbara's Story](https://www.moffitt.org/inspiring-stories/barbaras-story/ "Barbara's Story")
  * [Abrianna's Story](https://www.moffitt.org/inspiring-stories/abriannas-story/ "Abrianna's Story")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)[For Healthcare Professionals](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)
  * [ For Healthcare Professionals ](https://www.moffitt.org/for-healthcare-professionals/)
  * [ Clinical Programs and Services ](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-33)
  * [ Physician Relations ](https://www.moffitt.org/for-healthcare-professionals/physician-relations/)
  * [ Continuing Education ](https://www.moffitt.org/for-healthcare-professionals/continuing-education/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-35)


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-31)[Clinical Programs and Services](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-31)
  * [Adolescent Young Adult (AYA) Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/adolescent-young-adult-aya-program/ "Adolescent Young Adult \(AYA\) Program")
  * [Anesthesiology and Critical Care Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/anesthesiology-program/ "Anesthesiology and Critical Care Program")
  * [BMT and Cellular Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/bmt-and-cellular-immunotherapy-program/ "BMT and Cellular Immunotherapy Program")
  * [Breast Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/breast-oncology-program/ "Breast Oncology Program")
  * [Cardio-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cardio-oncology-program/ "Cardio-Oncology Program")
  * [Cutaneous Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/cutaneous-oncology-program/ "Cutaneous Oncology Program")
  * [Diagnostic Imaging and Interventional Radiology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/diagnostic-imaging-and-interventional-radiology-program/ "Diagnostic Imaging and Interventional Radiology Program")
  * [Endocrine Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endocrine-oncology-program/ "Endocrine Oncology Program")
  * [Endoscopic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/endoscopic-oncology-program/ "Endoscopic Oncology Program")
  * [Gastrointestinal Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gastrointestinal-oncology-program/ "Gastrointestinal Oncology Program")
  * [Genetic Counseling Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genetic-counseling-program/ "Genetic Counseling Program")
  * [Genitourinary Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/genitourinary-oncology-program/ "Genitourinary Oncology Program")
  * [Gynecologic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/gynecologic-oncology-program/ "Gynecologic Oncology Program")
  * [Head and Neck Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/head-and-neck-oncology-program/ "Head and Neck Oncology Program")
  * [Immunotherapy Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/immunotherapy-program/ "Immunotherapy Program")
  * [Malignant Hematology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/malignant-hematology-program/ "Malignant Hematology Program")
  * [Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/moffitt-malignant-hematology-cellular-therapy-at-memorial-healthcare-system/ "Moffitt Malignant Hematology Cellular Therapy at Memorial Healthcare System")
  * [Neuro-Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/neuro-oncology-program/ "Neuro-Oncology Program")
  * [Pathology](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pathology/ "Pathology")
  * [Pharmacy](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/pharmacy/ "Pharmacy")
  * [Radiation Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/radiation-oncology-program/ "Radiation Oncology Program")
  * [Sarcoma Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/sarcoma-program/ "Sarcoma Program")
  * [Screening Prevention](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/screening-prevention/ "Screening Prevention")
  * [Senior Adult Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/senior-adult-oncology-program/ "Senior Adult Oncology Program")
  * [Supportive Care Medicine Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/supportive-care-medicine-program/ "Supportive Care Medicine Program")
  * [Thoracic Oncology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/thoracic-oncology-program/ "Thoracic Oncology Program")
  * [Translational Pathology Program](https://www.moffitt.org/for-healthcare-professionals/clinical-programs-and-services/translational-pathology/ "Translational Pathology Program")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-31)[Continuing Education](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-31)
  * [Moffitt Grand Rounds](https://www.moffitt.org/for-healthcare-professionals/continuing-education/moffitt-grand-rounds/ "Moffitt Grand Rounds")
  * [Provider Conferences](https://www.moffitt.org/for-healthcare-professionals/continuing-education/provider-conferences/ "Provider Conferences")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)[Research](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)
  * [ Research Science ](https://www.moffitt.org/research-science/)
  * [ Research Programs ](https://www.moffitt.org/research-science/research-programs/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-39)
  * [ Divisions and Departments ](https://www.moffitt.org/research-science/divisions-and-departments/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-41)
  * [ Centers and Institutes ](https://www.moffitt.org/research-science/centers-and-institutes/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-43)
  * [ Community Outreach and Engagement ](https://www.moffitt.org/research-science/community-outreach-and-engagement/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-45)
  * [ Shared Resources ](https://www.moffitt.org/research-science/shared-resources/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-47)
  * [ Academic and Industry Partnerships ](https://www.moffitt.org/research-science/academic-and-industry-partnerships/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-49)
  * [ Administration ](https://www.moffitt.org/research-science/administration/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-51)


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)[Research Programs](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)
  * [Cancer Biology and Evolution](https://www.moffitt.org/research-science/research-programs/cancer-biology-and-evolution/ "Cancer Biology and Evolution")
  * [Cancer Epidemiology](https://www.moffitt.org/research-science/research-programs/cancer-epidemiology/ "Cancer Epidemiology")
  * [Health Outcomes and Behavior](https://www.moffitt.org/research-science/research-programs/health-outcomes-behavior/ "Health Outcomes and Behavior")
  * [Immuno-Oncology](https://www.moffitt.org/research-science/research-programs/immuno-oncology/ "Immuno-Oncology")
  * [Molecular Medicine](https://www.moffitt.org/research-science/research-programs/molecular-medicine/ "Molecular Medicine")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)[Divisions and Departments](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)
  * [Basic Science](https://www.moffitt.org/research-science/divisions-and-departments/basic-science/ "Basic Science")
  * [BioEngineering](https://www.moffitt.org/research-science/divisions-and-departments/bioengineering/ "BioEngineering")
  * [Clinical Science](https://www.moffitt.org/research-science/divisions-and-departments/clinical-science/ "Clinical Science")
  * [Population Science](https://www.moffitt.org/research-science/divisions-and-departments/population-science/ "Population Science")
  * [Quantitative Science](https://www.moffitt.org/research-science/divisions-and-departments/quantitative-science/ "Quantitative Science")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)[Centers and Institutes](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)
  * [Centers of Excellence](https://www.moffitt.org/research-science/centers-and-institutes/centers-of-excellence/ "Centers of Excellence")
  * [Institutes](https://www.moffitt.org/research-science/centers-and-institutes/institutes/ "Institutes")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)[Community Outreach and Engagement](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)
  * [About COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/about-coe/ "About COE")
  * [Advisory Boards](https://www.moffitt.org/research-science/community-outreach-and-engagement/community-advisory-boards/ "Advisory Boards")
  * [Catchment Area](https://www.moffitt.org/research-science/community-outreach-and-engagement/catchment-area/ "Catchment Area")
  * [Data](https://www.moffitt.org/research-science/community-outreach-and-engagement/data/ "Data")
  * [Outreach](https://www.moffitt.org/research-science/community-outreach-and-engagement/outreach/ "Outreach")
  * [Research and Clinical Trials](https://www.moffitt.org/research-science/community-outreach-and-engagement/research-and-clinical-trials/ "Research and Clinical Trials")
  * [Get Involved With COE](https://www.moffitt.org/research-science/community-outreach-and-engagement/get-involved-with-coe/ "Get Involved With COE")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)[Shared Resources](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)
  * [Analytic Microscopy](https://www.moffitt.org/research-science/shared-resources/analytic-microscopy/ "Analytic Microscopy")
  * [Biostatistics and Bioinformatics](https://www.moffitt.org/research-science/shared-resources/biostatistics-and-bioinformatics/ "Biostatistics and Bioinformatics")
  * [Cancer Pharmacokinetics and Pharmacodynamics](https://www.moffitt.org/research-science/shared-resources/cancer-pharmacokinetics-and-pharmacodynamics/ "Cancer Pharmacokinetics and Pharmacodynamics")
  * [Chemical Biology](https://www.moffitt.org/research-science/shared-resources/chemical-biology/ "Chemical Biology")
  * [Collaborative Data Services](https://www.moffitt.org/research-science/shared-resources/collaborative-data-services/ "Collaborative Data Services")
  * [Flow Cytometry](https://www.moffitt.org/research-science/shared-resources/flow-cytometry/ "Flow Cytometry")
  * [Gene Targeting](https://www.moffitt.org/research-science/shared-resources/gene-targeting/ "Gene Targeting")
  * [Molecular Genomics](https://www.moffitt.org/research-science/shared-resources/molecular-genomics/ "Molecular Genomics")
  * [Participant Research, Interventions, and Measurement Core (PRISM)](https://www.moffitt.org/research-science/shared-resources/participant-research-interventions-and-measurement-core-prism/ "Participant Research, Interventions, and Measurement Core \(PRISM\)")
  * [Proteomics and Metabolomics](https://www.moffitt.org/research-science/shared-resources/proteomics-and-metabolomics/ "Proteomics and Metabolomics")
  * [Quantitative Imaging Core](https://www.moffitt.org/research-science/shared-resources/quantitative-imaging-core/ "Quantitative Imaging Core")
  * [Small Animal Imaging Lab](https://www.moffitt.org/research-science/shared-resources/small-animal-imaging-lab/ "Small Animal Imaging Lab")
  * [Tissue](https://www.moffitt.org/research-science/shared-resources/tissue/ "Tissue")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)[Academic and Industry Partnerships](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)
  * [Office of Innovation](https://www.moffitt.org/research-science/academic-and-industry-partnerships/office-of-innovation/ "Office of Innovation")
  * [Academic Partnerships](https://www.moffitt.org/research-science/academic-and-industry-partnerships/academic-partnerships/ "Academic Partnerships")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)[Administration](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-37)
  * [Non-Therapeutic Research Office](https://www.moffitt.org/research-science/administration/non-therapeutic-research-office/ "Non-Therapeutic Research Office")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)[Training & Education](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)
  * [ Education ](https://www.moffitt.org/education/)
  * [ Medical Education ](https://www.moffitt.org/education/medical-education/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-55)
  * [ Research Education and Training ](https://www.moffitt.org/education/research-education-and-training/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-57)
  * [ Nursing Education ](https://www.moffitt.org/education/nursing-education/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-59)
  * [ Health Professional Education ](https://www.moffitt.org/education/health-professional-education/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-61)
  * [ Other Educational Programs ](https://www.moffitt.org/education/other-educational-programs/)


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)[Medical Education](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)
  * [Our Training Programs](https://www.moffitt.org/education/medical-education/our-training-programs/ "Our Training Programs")
  * [Program Staff/Contact Us](https://www.moffitt.org/education/medical-education/program-staffcontact-us/ "Program Staff/Contact Us")
  * [Salary and Benefits](https://www.moffitt.org/education/medical-education/salary-and-benefits/ "Salary and Benefits")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)[Research Education and Training](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)
  * [Office of Postdoctoral Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-postdoctoral-affairs/ "Office of Postdoctoral Affairs")
  * [Office of Graduate Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-graduate-affairs/ "Office of Graduate Affairs")
  * [Office of Undergraduate and Visiting Scholar Affairs](https://www.moffitt.org/education/research-education-and-training/office-of-undergraduate-and-visiting-scholar-affairs/ "Office of Undergraduate and Visiting Scholar Affairs")
  * [Pre-College Programs](https://www.moffitt.org/education/research-education-and-training/pre-college-programs/ "Pre-College Programs")
  * [What We Provide](https://www.moffitt.org/education/research-education-and-training/what-we-provide/ "What We Provide")
  * [Contact Us](https://www.moffitt.org/education/research-education-and-training/contact-us/ "Contact Us")
  * [About Tampa Bay](https://www.moffitt.org/careers/about-tampa-bay/ "About Tampa Bay")
  * [News](https://www.moffitt.org/education/research-education-and-training/news/ "News")
  * [Where Are They Now](https://www.moffitt.org/education/research-education-and-training/where-are-they-now/ "Where Are They Now")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)[Nursing Education](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)
  * [Ambulatory Care Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/ambulatory-care-oncology-nurse-residency-program/ "Ambulatory Care Oncology Nurse Residency Program")
  * [Nurse Anesthetist](https://www.moffitt.org/education/nursing-education/nurse-anesthetist/ "Nurse Anesthetist")
  * [Nurse Practitioner](https://www.moffitt.org/education/nursing-education/nurse-practitioner/ "Nurse Practitioner")
  * [Oncology Nurse Residency Program](https://www.moffitt.org/education/nursing-education/oncology-nurse-residency-program/ "Oncology Nurse Residency Program")
  * [Registered Nurse](https://www.moffitt.org/education/nursing-education/registered-nurse/ "Registered Nurse")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)[Health Professional Education](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-53)
  * [Advanced Pharmacy Practice (APPE)](https://www.moffitt.org/education/health-professional-education/advanced-pharmacy-practice-appe/ "Advanced Pharmacy Practice \(APPE\)")
  * [Anesthesiology Assistant](https://www.moffitt.org/education/health-professional-education/anesthesiology-assistant/ "Anesthesiology Assistant")
  * [Dietetic Technician](https://www.moffitt.org/education/health-professional-education/dietetic-technician/ "Dietetic Technician")
  * [Dietitian](https://www.moffitt.org/education/health-professional-education/dietitian/ "Dietitian")
  * [Genetic Counseling](https://www.moffitt.org/education/health-professional-education/genetic-counseling/ "Genetic Counseling")
  * [Introductory Pharmacy Practice (IPPE)](https://www.moffitt.org/education/health-professional-education/introductory-pharmacy-practice-ippe/ "Introductory Pharmacy Practice \(IPPE\)")
  * [Master of Public Health Field Experience](https://www.moffitt.org/education/health-professional-education/master-of-public-health-field-experience/ "Master of Public Health Field Experience")
  * [Medical Assistants](https://www.moffitt.org/education/health-professional-education/medical-assistants/ "Medical Assistants")
  * [Nuclear Medicine](https://www.moffitt.org/education/health-professional-education/nuclear-medicine/ "Nuclear Medicine")
  * [Occupational Therapy Intern](https://www.moffitt.org/education/health-professional-education/occupational-therapy-intern/ "Occupational Therapy Intern")
  * [PGY1 Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-1-residency/ "PGY1 Pharmacy Residency")
  * [PGY2 Oncology Pharmacy Residency](https://www.moffitt.org/education/health-professional-education/pgy-2-oncology-residency/ "PGY2 Oncology Pharmacy Residency")
  * [Oncology Pharmacy Technician Trainee Program](https://www.moffitt.org/education/health-professional-education/pharmacy-technician-extern/ "Oncology Pharmacy Technician Trainee Program")
  * [Physical Therapy](https://www.moffitt.org/education/health-professional-education/physical-therapy/ "Physical Therapy")
  * [Physical Therapy Assistant](https://www.moffitt.org/education/health-professional-education/physical-therapy-assistant/ "Physical Therapy Assistant")
  * [Physician Assistant](https://www.moffitt.org/education/health-professional-education/physician-assistant/ "Physician Assistant")
  * [Psychology](https://www.moffitt.org/education/health-professional-education/psychology/ "Psychology")
  * [Radiation Therapy](https://www.moffitt.org/education/health-professional-education/radiation-therapy/ "Radiation Therapy")
  * [Radiography Therapy](https://www.moffitt.org/education/health-professional-education/radiography-therapy/ "Radiography Therapy")
  * [Respiratory Therapy](https://www.moffitt.org/education/health-professional-education/respiratory-therapy/ "Respiratory Therapy")
  * [Social Work](https://www.moffitt.org/education/health-professional-education/social-work/ "Social Work")
  * [Sonography/Ultrasound Student](https://www.moffitt.org/education/health-professional-education/sonographyultrasound-student/ "Sonography/Ultrasound Student")
  * [Speech Therapy](https://www.moffitt.org/education/health-professional-education/speech-therapy/ "Speech Therapy")
  * [Wound Ostomy](https://www.moffitt.org/education/health-professional-education/wound-ostomy/ "Wound Ostomy")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)[Give](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-1)
  * [ Give ](https://www.moffitt.org/give/)
  * [ Why Give? ](https://www.moffitt.org/give/why-give/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-65)
  * [ Ways to Give ](https://www.moffitt.org/give/ways-to-give/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-67)
  * [ Get Involved ](https://www.moffitt.org/give/get-involved/) [](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-69)


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-63)[Why Give?](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-63)
  * [About the Moffitt Foundation](https://www.moffitt.org/give/why-give/about-the-moffitt-foundation/ "About the Moffitt Foundation")
  * [FAQ](https://www.moffitt.org/give/why-give/faq/ "FAQ")
  * [Financials and Stewardship](https://www.moffitt.org/give/why-give/financials-and-stewardship/ "Financials and Stewardship")
  * [Contact the Foundation](https://www.moffitt.org/give/why-give/contact-the-foundation/ "Contact the Foundation")
  * [You Can Make a Difference](https://www.moffitt.org/give/why-give/you-can-make-a-difference/ "You Can Make a Difference")
  * [Impact Report](https://www.moffitt.org/give/your-impact/2022-annual-foundation-impact-report/ "Impact Report")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-63)[Ways to Give](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-63)
  * [Cash, Stock or Other Assets](https://www.moffitt.org/give/ways-to-give/cash-stock-or-other-assets/ "Cash, Stock or Other Assets")
  * [Planned Giving](https://mymoffittlegacy.org/ "Planned Giving")
  * [Philanthropic Foundation Giving](https://www.moffitt.org/give/ways-to-give/philanthropic-foundation-giving/ "Philanthropic Foundation Giving")
  * [Corporate Partnership](https://www.moffitt.org/give/ways-to-give/corporate-partnership/ "Corporate Partnership")
  * [Employer Matching Gifts](https://www.moffitt.org/give/ways-to-give/employer-matching-gifts/ "Employer Matching Gifts")
  * [Endowment Gifts](https://www.moffitt.org/give/ways-to-give/endowment-gifts/ "Endowment Gifts")
  * [Other Ways to Donate](https://www.moffitt.org/give/ways-to-give/other-ways-to-donate/ "Other Ways to Donate")
  * [Breast Cancer Funding Opportunities](https://www.moffitt.org/give/ways-to-give/breast-cancer-funding-opportunities/ "Breast Cancer Funding Opportunities")
  * [Support the Pentecost Family Myeloma Research Center](https://www.moffitt.org/give/ways-to-give/support-the-pentecost-family-myeloma-research-center/ "Support the Pentecost Family Myeloma Research Center")
  * [Partners In Discovery](https://www.moffitt.org/give/ways-to-give/partners-in-discovery/ "Partners In Discovery")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-63)[Get Involved](https://www.moffitt.org/research-science/researchers/rami-komrokji#mm-63)
  * [Become a Member](https://www.moffitt.org/give/get-involved/become-a-member/ "Become a Member")
  * [Volunteer Your Time](https://www.moffitt.org/give/get-involved/volunteer-your-time/ "Volunteer Your Time")
  * [Miles for Moffitt](https://www.moffitt.org/give/get-involved/miles-for-moffitt/ "Miles for Moffitt")
  * [Magnolia](https://www.moffitt.org/give/get-involved/magnolia/ "Magnolia")
  * [Mission Possible Sarasota Luncheon](https://www.moffitt.org/give/get-involved/mission-possible-sarasota-luncheon/ "Mission Possible Sarasota Luncheon")
  * [Discovery Series Webinars](https://www.moffitt.org/give/get-involved/discovery-series-webinars/ "Discovery Series Webinars")
  * [Fundraise for Moffitt](https://www.moffitt.org/give/get-involved/fundraise-for-moffitt/ "Fundraise for Moffitt")


[](https://www.moffitt.org/research-science/researchers/rami-komrokji#page)
